Skip to main content
UniHealth

Doctor search

Ian Churchhill Anderson, MD

Hematology/Oncology · Santa Rosa

NPI 1518055573

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
3
1 carrier
Offices
5
Since medical school
38 years
Duke University School of Medicine, 1988

Offices

5 locations · Providence Medical Foundation · 1,461 clinicians in this group

Looking this up.

Hospitals listed: Adventist Health Mendocino Coast · Healdsburg Hospital · Petaluma Valley Hospital · Providence Santa Rosa Memorial Hospital · Sonoma Valley Hospital. That is not proof they admit you there this week.

Plans that list them

3 plans · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Anderson’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Plans whose provider directory lists this clinician
Imperial Courage Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Dynamic Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Senior Value (HMO C-SNP)Imperial Health Plan of California, Inc.ListedSep 1, 2026

California Medical Board record

Licence A49481 · Current

Licensed to practise in California · since 2000 · expires 2027-11-30 · Duke University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

  • American Board of Internal Medicine - Medical Oncology

Hospitals they work in

5 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Adventist Health Mendocino CoastFort Bragg, CACritical Access Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 5 of 5 · 80% would definitely recommend it
    Overall rating: 3 of 5 starsNo measure marked better or worse than the national rate
  • Healdsburg HospitalHealdsburg, CACritical Access Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Providence, which runs 54 hospitals in 7 states77% would definitely recommend it
    No overall ratingNo measure marked better or worse than the national rate
  • Petaluma Valley HospitalPetaluma, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 70% would definitely recommend it
    Overall rating: 4 of 5 starsNo measure marked better or worse than the national rate
  • Providence Santa Rosa Memorial HospitalSanta Rosa, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 69% would definitely recommend it
    Overall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.375, Oct 2024 – Sep 2025
  • Sonoma Valley HospitalSonoma, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency departmentPatients rate it 4 of 5 · 79% would definitely recommend it
    Overall rating: 2 of 5 starsNo measure marked better or worse than the national rate
See every measure and the patient survey for Adventist Health Mendocino Coast

Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Adventist Health Mendocino Coast
Death rate for heart failure patientsComplications and deaths9 · 63 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths17.2 · 103 casesNoneJul 2022 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.7 · 268 casesNoneJul 2024 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 78 casesNoneJul 2023 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-24.2 · 83 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits26.7 · 102 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits17.2 · 101 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits7.7 (5.2 to 11.1) · 65 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.5 (7.3 to 14.6) · 65 casesNo differentJan 2024 – Dec 2024
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.1 (9.8 to 17.4) · 526 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.7 to 1.5) · 48 casesNo differentJan 2024 – Dec 2024

What patients said (119 patients answered, 22% of those asked)

Patient survey stars by topic at Adventist Health Mendocino Coast
Cleanliness5
Nurse communication5
Doctor communication5
Communication about medicines4
Discharge information5
Overall hospital rating5
Quietness4
Recommend hospital5
Share of patients giving the best answer at Adventist Health Mendocino Coast
Room was "always" clean86%
Nurses "always" communicated well86%
Doctors "always" communicated well89%
Staff "always" explained72%
Yes, staff "did" give patients this information94%
Yes, staff "did" give patients information about help after discharge94%
Doctors "always" explained things so they could understand85%
Doctors "always" listened carefully87%
Doctors "always" treated them with courtesy and respect96%
Patients who gave a rating of "9" or "10" (high)86%
Staff "always" explained new medications87%
Nurses "always" explained things so they could understand82%
Nurses "always" listened carefully84%
Nurses "always" treated them with courtesy and respect92%
"Always" quiet at night56%
"YES", patients would definitely recommend the hospital80%
Staff "always" explained possible side effects57%
Yes, staff "did" give patients information about possible symptoms93%
See every measure and the patient survey for Healdsburg Hospital

Behind the star rating — Deaths: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 2 the same, 1 worse of 3 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Healdsburg Hospital
Death rate for pneumonia patientsComplications and deaths16.5 · 45 casesNoneJul 2022 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.7 · 109 casesNoneJul 2024 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits35.8 · 47 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits17.5 · 31 casesNoneJul 2023 – Jun 2025
Share of patients giving the best answer at Healdsburg Hospital
Room was "always" clean83%
Nurses "always" communicated well83%
Doctors "always" communicated well78%
Staff "always" explained64%
Yes, staff "did" give patients this information94%
Yes, staff "did" give patients information about help after discharge96%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully77%
Doctors "always" treated them with courtesy and respect85%
Patients who gave a rating of "9" or "10" (high)76%
Staff "always" explained new medications79%
Nurses "always" explained things so they could understand84%
Nurses "always" listened carefully69%
Nurses "always" treated them with courtesy and respect95%
"Always" quiet at night54%
"YES", patients would definitely recommend the hospital77%
Staff "always" explained possible side effects49%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Petaluma Valley Hospital

Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 0 better, 6 the same, 1 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Petaluma Valley Hospital
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.31 (0.23 to 2.39) · 147 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.89 (0.44 to 1.33)No differentJul 2022 – Jun 2024
Death rate for COPD patientsComplications and deaths8.6 · 49 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths11.6 · 118 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths14.9 · 154 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths12.7 · 57 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths4 · 533 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.2 (0 to 0.43) · 1,427 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.26 (0.04 to 0.47) · 1,398 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.15 (0.64 to 5.65) · 216 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.66 (0 to 3.39) · 43 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.27 (0.56 to 3.98) · 202 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.61 (0 to 18.36) · 49 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.16 (0.85 to 9.47) · 44 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.73 (0.21 to 3.25) · 45 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.37 (0 to 1.41) · 1,184 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths6.1 · 26 casesNoneApr 2023 – Mar 2025
Clostridium Difficile (C.Diff)Infections0.308No differentOct 2024 – Sep 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits21.7 · 103 casesNoneJul 2023 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits6.6 · 110 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-3 · 143 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits17.4 · 131 casesNoneJul 2023 – Jun 2025
Rate of readmission after hip/knee replacementUnplanned return visits6 · 26 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 52 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.3 (9.8 to 17.8) · 364 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1.1 (0.8 to 1.5) · 138 casesNo differentJan 2024 – Dec 2024

What patients said (246 patients answered, 23% of those asked)

Patient survey stars by topic at Petaluma Valley Hospital
Cleanliness5
Nurse communication3
Doctor communication2
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital3
Share of patients giving the best answer at Petaluma Valley Hospital
Room was "always" clean85%
Nurses "always" communicated well75%
Doctors "always" communicated well74%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge86%
Doctors "always" explained things so they could understand69%
Doctors "always" listened carefully72%
Doctors "always" treated them with courtesy and respect80%
Patients who gave a rating of "9" or "10" (high)67%
Staff "always" explained new medications73%
Nurses "always" explained things so they could understand68%
Nurses "always" listened carefully72%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night45%
"YES", patients would definitely recommend the hospital70%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Providence Santa Rosa Memorial Hospital

Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Providence Santa Rosa Memorial Hospital
Clostridium Difficile (C.Diff)Infections0.375BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.19 (0.26 to 2.13) · 1,736 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.76 (0.48 to 1.03)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths181.27 (137.92 to 224.62) · 109 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.1 · 72 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.8 · 129 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.3 · 226 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths11.2 · 530 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths13.2 · 448 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.3 · 245 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.2 · 2,733 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.22 (0.03 to 0.4) · 8,115 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.23 (0.04 to 0.41) · 8,057 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths2.37 (0.56 to 4.18) · 2,186 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.59 (0.1 to 3.08) · 772 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.27 (0.9 to 3.63) · 1,999 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths5.74 (0.06 to 11.42) · 810 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths4.04 (0.53 to 7.55) · 768 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.8 (0.38 to 3.21) · 401 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.46 (0 to 1) · 7,051 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.3 · 77 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.915No differentOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.552No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.297No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.353No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 288 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 489 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits0.4 · 259 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-0.4 · 580 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits7.5 · 456 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits17.2 · 431 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.4 (4.9 to 8.3) · 584 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.3 (8.2 to 12.7) · 584 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6.1 · 72 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.4 · 64 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20.2 · 133 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.5 (10.8 to 16.7) · 2,810 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1.2 (1 to 1.5) · 780 casesNo differentJan 2024 – Dec 2024

What patients said (473 patients answered, 23% of those asked)

Patient survey stars by topic at Providence Santa Rosa Memorial Hospital
Cleanliness4
Nurse communication3
Doctor communication2
Communication about medicines2
Discharge information3
Overall hospital rating3
Quietness1
Recommend hospital4
Share of patients giving the best answer at Providence Santa Rosa Memorial Hospital
Room was "always" clean71%
Nurses "always" communicated well76%
Doctors "always" communicated well74%
Staff "always" explained56%
Yes, staff "did" give patients this information87%
Yes, staff "did" give patients information about help after discharge85%
Doctors "always" explained things so they could understand68%
Doctors "always" listened carefully72%
Doctors "always" treated them with courtesy and respect82%
Patients who gave a rating of "9" or "10" (high)66%
Staff "always" explained new medications68%
Nurses "always" explained things so they could understand72%
Nurses "always" listened carefully72%
Nurses "always" treated them with courtesy and respect85%
"Always" quiet at night37%
"YES", patients would definitely recommend the hospital69%
Staff "always" explained possible side effects45%
Yes, staff "did" give patients information about possible symptoms89%
See every measure and the patient survey for Sonoma Valley Hospital

Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 6 the same, 0 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Sonoma Valley Hospital
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.11 (0.63 to 1.6)No differentJul 2022 – Jun 2024
Death rate for COPD patientsComplications and deaths8.2 · 37 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths11 · 41 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths16.6 · 106 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 35 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths5.6 · 345 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.21 (0 to 0.44) · 713 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.27 (0.05 to 0.48) · 660 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.36 (0.77 to 5.94) · 101 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.65 (0 to 3.38) · 27 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.31 (0.58 to 4.03) · 100 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.86 (0 to 18.76) · 28 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (0.84 to 9.45) · 27 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths1.12 (0 to 2.33) · 540 casesNo differentJul 2022 – Jun 2024
Clostridium Difficile (C.Diff)Infections0.651No differentOct 2024 – Sep 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits21.1 · 60 casesNoneJul 2023 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits15.5 · 47 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits7.1 · 100 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits18 · 105 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.7 · 47 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.6 (10.2 to 17.9) · 486 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.9 (0.6 to 1.3) · 83 casesNo differentJan 2024 – Dec 2024

What patients said (164 patients answered, 31% of those asked)

Patient survey stars by topic at Sonoma Valley Hospital
Cleanliness4
Nurse communication5
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness3
Recommend hospital4
Share of patients giving the best answer at Sonoma Valley Hospital
Room was "always" clean74%
Nurses "always" communicated well85%
Doctors "always" communicated well88%
Staff "always" explained65%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand84%
Doctors "always" listened carefully88%
Doctors "always" treated them with courtesy and respect92%
Patients who gave a rating of "9" or "10" (high)74%
Staff "always" explained new medications77%
Nurses "always" explained things so they could understand81%
Nurses "always" listened carefully82%
Nurses "always" treated them with courtesy and respect91%
"Always" quiet at night52%
"YES", patients would definitely recommend the hospital79%
Staff "always" explained possible side effects53%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$195,376

Medicare paid this office $195,376 for 630 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Return visit (30+ min)505$133,468$102
Long return visit (40+ min)119$24,148$146
New patient visit (60+ min)62$11,640$188
New patient visit (45+ min)60$7,760$129
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes36$5,187$96
See all 8 services
Every Original Medicare service billed
Return visit (30+ min)505$133,468$102
Long return visit (40+ min)119$24,148$146
New patient visit (60+ min)62$11,640$188
New patient visit (45+ min)60$7,760$129
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes36$5,187$96
Short return visit (20+ min)52$3,918$65
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes26$2,836$62
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's115$2,182$13

Who their Medicare patients are

630 Original Medicare patients in 2024. Average age 76 · Under 65 5% · 85 and older 15% · Women 61% · Also on Medicaid 16% · Health risk score 2.14. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.

Conditions among them: High blood pressure 65% · Cancer 56% · Coronary heart disease 27% · Atrial fibrillation 25% · Chronic kidney disease 24% · Diabetes 23% · Depression 22% · Heart failure 20% · COPD 19% · Stroke 10% · Dementia 6%.

The office billed $827,538, Medicare allowed $263,400 and paid $195,376; for 1,963 services of 17 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20246301,963762.14$827,538$195,376
20236321,828762.02$653,812$191,726
20226102,063761.98$713,049$224,415
20215812,015752.19$385,060$209,006
20205721,929752.26$369,360$169,676
20196432,295742.18$440,676$202,922
20186511,989752.30$372,053$167,345
20176372,122742.19$356,337$172,716
20165912,112752.04$343,977$167,550
20156171,983741.96$292,563$155,322
201487843,010741.95$1,729,272$617,359
20131,355156,390741.94$6,177,028$2,163,133

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 9 services

Original Medicare services billed in 2023
Return visit (30+ min)473$120,375$100
Long return visit (40+ min)124$26,628$140
New patient visit (60+ min)77$13,482$175
New patient visit (45+ min)63$7,957$126
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes44$6,506$93
Short return visit (20+ min)67$5,504$69
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes41$5,262$65
Telephone medical discussion with physician, 21-30 minutes19$2,201$105
Initial hospital care with moderate level of medical decision making at least 75 minutes12$1,730$144

2022: 11 services

Original Medicare services billed in 2022
Return visit (30+ min)436$122,398$108
Long return visit (40+ min)138$34,524$156
New patient visit (60+ min)80$15,102$189
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes52$9,018$60
Telephone medical discussion with physician, 21-30 minutes67$8,369$105
New patient visit (45+ min)62$8,149$131
Short return visit (20+ min)80$7,882$76
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes45$7,411$87
Telephone medical discussion with physician, 11-20 minutes63$5,820$74
Initial hospital care with moderate level of medical decision making at least 75 minutes13$2,195$169
Telephone medical discussion with physician, 5-10 minutes37$2,025$48

2021: 10 services

Original Medicare services billed in 2021
Return visit (30+ min)440$133,868$103
Long return visit (40+ min)88$18,493$154
Short return visit (20+ min)112$10,611$75
New patient visit (60+ min)54$10,310$191
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes51$8,664$88
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes56$7,748$61
Initial hospital care with moderate level of medical decision making at least 75 minutes29$5,997$171
New patient visit (45+ min)38$5,320$140
Telephone medical discussion with physician, 21-30 minutes29$3,325$101
Telephone medical discussion with physician, 11-20 minutes36$3,075$70

2020: 8 services

Original Medicare services billed in 2020
Return visit (30+ min)448$114,202$86
New patient visit (60+ min)64$10,524$164
Long return visit (40+ min)67$9,310$121
Short return visit (20+ min)113$9,008$58
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes56$8,968$62
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes40$6,202$90
Initial hospital care with moderate level of medical decision making at least 75 minutes23$5,391$174
New patient visit (45+ min)35$4,550$130

2019: 9 services

Original Medicare services billed in 2019
Return visit (30+ min)494$133,248$85
New patient visit (60+ min)91$14,781$162
Long return visit (40+ min)84$12,494$120
Short return visit (20+ min)135$10,972$60
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes45$8,182$61
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes46$7,365$87
New patient visit (45+ min)58$7,321$126
Initial hospital care with moderate level of medical decision making at least 75 minutes21$5,730$169
Office for the evaluation and management of established patient that may not require presence of healthcare professional11$220$17

2018: 9 services

Original Medicare services billed in 2018
Return visit (30+ min)472$101,494$80
Long return visit (40+ min)97$13,419$109
New patient visit (60+ min)74$12,119$164
Short return visit (20+ min)141$10,127$53
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes35$6,608$83
Initial hospital care with moderate level of medical decision making at least 75 minutes37$6,503$163
New patient visit (45+ min)49$6,414$131
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes44$6,152$57
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes18$2,078$109

2017: 10 services

Original Medicare services billed in 2017
Return visit (30+ min)398$100,217$83
Short return visit (20+ min)213$16,592$52
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes54$10,363$85
New patient visit (60+ min)62$10,060$162
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes58$9,646$59
Long return visit (40+ min)71$9,428$115
New patient visit (45+ min)55$7,154$130
Initial hospital care with moderate level of medical decision making at least 75 minutes30$5,108$165
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes17$1,889$111
Office for the evaluation and management of established patient that may not require presence of healthcare professional14$375$14

2016: 11 services

Original Medicare services billed in 2016
Return visit (30+ min)376$92,883$83
Short return visit (20+ min)273$21,408$53
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes68$11,687$57
Long return visit (40+ min)76$11,044$116
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes48$8,587$83
New patient visit (45+ min)61$7,399$121
Initial hospital care with moderate level of medical decision making at least 75 minutes20$5,145$161
New patient visit (60+ min)31$5,087$164
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes11$1,194$109
New patient visit (30+ min)12$1,039$87
Office for the evaluation and management of established patient that may not require presence of healthcare professional11$228$15

2015: 11 services

Original Medicare services billed in 2015
Return visit (30+ min)309$79,678$86
Short return visit (20+ min)362$33,306$57
New patient visit (45+ min)87$11,668$134
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes63$8,764$59
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes38$5,331$85
Long return visit (40+ min)30$4,176$119
New patient visit (60+ min)24$4,058$169
Initial hospital care with moderate level of medical decision making at least 75 minutes14$2,305$165
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes14$1,558$111
New patient visit (30+ min)16$1,331$83
Office for the evaluation and management of established patient that may not require presence of healthcare professional20$333$15

2014: 38 services

Original Medicare services billed in 2014
Return visit (30+ min)294$73,028$85
Injection, denosumab, 1 mg29$47,606None
Injection, pegfilgrastim, 6 mg12$43,001None
Short return visit (20+ min)325$28,592$56
Injection, darbepoetin alfa, 1 microgram (non-esrd use)39$24,320None
Administration of chemotherapy into vein, 1 hour or less53$11,168$102
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes63$7,443$58
Injection, palonosetron hcl, 25 mcg26$7,039None
New patient visit (45+ min)46$6,059$132
Long return visit (40+ min)39$5,640$118
New patient visit (60+ min)34$5,457$161
Blood test, comprehensive group of blood chemicals321$4,933$12
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes39$4,696$84
Injection of additional new drug or substance into vein58$4,604$17
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count220$3,820$10
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle36$2,913$57
Administration of additional new drug or substance into vein, 1 hour or less25$2,772$51
New patient visit (30+ min)28$2,460$88
Injection of drug or substance under skin or into muscle71$2,201$18
Initial hospital care with moderate level of medical decision making at least 75 minutes11$2,125$163
Short return visit55$1,842$30
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes12$1,329$111
Administration of chemotherapy into vein, each additional hour23$1,044$23
Insertion of needle into vein for collection of blood sample196$930$3
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less19$905$36
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle18$720$24
Lactate dehydrogenase (enzyme) level116$675$5
Office for the evaluation and management of established patient that may not require presence of healthcare professional31$650$15
Injection, paclitaxel, 30 mg11$539None
Injection, carboplatin, 50 mg14$475None
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less12$427$24
Blood test, basic group of blood chemicals (calcium, total)15$260$11
Injection, dexamethasone sodium phosphate, 1 mg46$134None
Injection, granisetron hydrochloride, 100 mcg15$114None
Injection, ranitidine hydrochloride, 25 mg13$54None
Injection, diphenhydramine hcl, up to 50 mg26$24None
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg11$23None
Infusion, normal saline solution, sterile (500 ml = 1 unit)11$6None

2013: 69 services

Original Medicare services billed in 2013
Injection, rituximab, 100 mg37$283,025None
Injection, denosumab, 1 mg56$215,955None
Injection, bevacizumab, 10 mg15$193,960None
Injection, trastuzumab, excludes biosimilar, 10 mg14$173,000None
Injection, pegfilgrastim, 6 mg43$153,627None
Injection, darbepoetin alfa, 1 microgram (non-esrd use)73$87,129None
Injection, bortezomib, 0.1 mg12$70,360None
Injection, immune globulin, (flebogamma/flebogamma dif), intravenous, non-lyophilized (e.g., liquid), 500 mg13$64,969None
Administration of chemotherapy into vein, 1 hour or less158$61,887$119
Return visit (30+ min)280$61,055$86
Injection, fulvestrant, 25 mg11$58,720None
Short return visit (20+ min)358$34,036$58
Injection, palonosetron hcl, 25 mcg79$31,429None
Blood test, comprehensive group of blood chemicals793$19,616$13
Injection of additional new drug or substance into vein148$18,659$19
Leuprolide acetate (for depot suspension), 7.5 mg18$18,274None
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count488$14,770$11
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle70$14,559$60
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)29$13,965$1
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes68$11,228$57
Injection, zoledronic acid (zometa), 1 mg11$11,058None
Administration of additional new drug or substance into vein, 1 hour or less67$10,512$60
Injection, fosaprepitant, 1 mg21$9,601None
Injection of drug or substance under skin or into muscle161$9,443$21
New patient visit (60+ min)39$6,338$163
Administration of chemotherapy into vein, each additional hour66$5,883$25
New patient visit (45+ min)44$5,746$131
Long return visit (40+ min)41$5,363$114
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less36$4,183$60
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg22$4,119None
Administration of additional new drug or substance into vein using push technique21$3,581$53
Insertion of needle into vein for collection of blood sample427$3,297$3
Administration of prolonged chemotherapy into vein12$3,245$120
Short return visit75$2,933$35
Carcinoembryonic antigen (cea) protein level79$2,823$26
Injection of drug or substance into vein35$2,810$47
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less33$2,762$27
Lactate dehydrogenase (enzyme) level305$2,588$5
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle32$2,386$26
Injection, carboplatin, 50 mg44$2,366None
Initial hospital care with moderate level of medical decision making at least 75 minutes13$2,228$159
Injection, paclitaxel, 30 mg26$2,121None
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour24$1,819$18
Biopsy of bone marrow12$1,791$138
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes17$1,785$105
New patient visit (30+ min)21$1,761$84
Irrigation of implanted venous access drug delivery device33$1,130$21
Blood creatinine level129$941$7
Immunologic analysis for detection of tumor antigen, quantitative; ca 12518$772$29
Blood test, basic group of blood chemicals (calcium, total)55$769$11
Immunologic analysis for detection of tumor antigen, quantitative; ca 15-321$724$28
Psa (prostate specific antigen) measurement, total20$657$25
Infusion into a vein for hydration, each additional hour21$652$12
Injection, granisetron hydrochloride, 100 mcg50$593None
Collection of blood sample from implanted device25$587$18
Office for the evaluation and management of established patient that may not require presence of healthcare professional22$559$17
Injection, fluorouracil, 500 mg15$503None
Injection, dexamethasone sodium phosphate, 1 mg137$476None
Injection, etoposide, 10 mg12$474None
Magnesium level36$426$9
Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion11$327$16
Injection, ranitidine hydrochloride, 25 mg26$146None
Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service12$131$10
Red blood cell sedimentation rate, to detect inflammation, non-automated25$125$5
Injection, hydrocortisone sodium succinate, up to 100 mg11$102None
Injection, diphenhydramine hcl, up to 50 mg58$84None
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg24$31None
Infusion, normal saline solution , 1000 cc16$29None
Injection, magnesium sulfate, per 500 mg11$22None

Medicaid work

$13,069 in 2024

Medicaid paid $13,069 for 340 billed services this clinician did in 2024, up to 35 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Return visit (30+ min)312$12,929
Screening for depression is documented as negative, a follow-up plan is not required28$140
Medicaid work by year
2024340235$13,069
2023330234$11,860
2022210134$9,300
2021251225$14,917
2020175130$12,198
2019214127$14,506
2018213125$14,692
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Return visit (30+ min)301$11,715
Screening for depression is documented as negative, a follow-up plan is not required29$145

2022

Largest Medicaid services in 2022
Return visit (30+ min)210$9,300

2021

Largest Medicaid services in 2021
Return visit (30+ min)228$13,739
SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES23$1,178

2020

Largest Medicaid services in 2020
Return visit (30+ min)175$12,198

2019

Largest Medicaid services in 2019
Return visit (30+ min)214$14,506

2018

Largest Medicaid services in 2018
Return visit (30+ min)213$14,692

Drugs they prescribed that Part D paid

$5,747,660

Pharmacies billed $5,747,660 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 8% of their Part D prescriptions (152 of 2,030) in 2024. Above the middle of the specialty; the typical hematology-oncology clinician is at 5%. Long-acting opioids: 11% of their opioid prescriptions.

1,557 generic and fewer than 11 brand-name prescriptions · $5,747,660 in drug cost · 31 antibiotic prescriptions to 22 people · 37 antipsychotic prescriptions to people over 65.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Tagrisso47$765,286$16,283
Verzenio41$520,617$12,698
Ibrance32$516,927$16,154
Imbruvica38$511,250$13,454
Alecensa26$482,565$18,560
See all 44 drugs
Every Part D drug this clinician prescribed
Tagrisso47$765,286$16,283
Verzenio41$520,617$12,698
Ibrance32$516,927$16,154
Imbruvica38$511,250$13,454
Alecensa26$482,565$18,560
Lenalidomide42$473,451$11,273
Jakafi24$395,264$16,469
Calquence23$343,365$14,929
Revlimid14$224,221$16,016
Abiraterone Acetate41$75,436$1,840
Eliquis47$37,008$787
Imatinib Mesylate18$26,379$1,466
Xarelto22$17,933$815
Letrozole167$5,024$30
Exemestane37$4,091$111
Potassium Chloride87$2,419$28
Oxycodone54$1,394$26
Tamoxifen Citrate87$1,323$15
Ondansetron56$1,238$22
Prochlorperazine Maleate90$927$10
Dexamethasone91$887$10
Hydrocodone-Acetaminophen32$669$21
Anastrozole23$665$29
Hydroxyurea38$643$17
Ondansetron Odt29$610$21
Gabapentin28$436$16
Hydromorphone16$381$24
Diphenoxylate-Atropine17$371$22
Albuterol Sulfate Hfa15$334$22
Hydrocortisone11$303$28
Lorazepam62$294$5
Olanzapine43$271$6
Tamsulosin13$255$20
Prednisone74$224$3
Acyclovir24$222$9
Klor-Con 1020$207$10
Pantoprazole16$207$13
Omeprazole21$198$9
Zolpidem29$150$5
Levothyroxine24$136$6
Tramadol17$128$8
Famotidine14$99$7
Citalopram Hbr14$74$5
Lisinopril14$63$4

Year by year

Part D prescribing by year
20242,0303668% (152)None$5,747,660
20232,1833898% (181)None$5,825,409
20221,9763518% (161)None$7,001,416
20212,0852977% (144)None$6,599,359
20201,9522888% (157)None$5,374,034
20191,9633068% (161)30%$4,281,070
20181,8972668% (148)25%$3,128,642
20171,6152517% (112)None$2,630,959
20161,55027010% (161)18%$1,783,632
20151,42522713% (187)None$1,214,697
20141,32522512% (161)18%$1,097,767
20131,24521416% (198)None$1,030,091

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 46 drugs

Part D drugs prescribed in 2023
Revlimid35$670,370$19,153
Jakafi25$452,847$18,114
Ibrance29$437,302$15,079
Lenalidomide32$432,085$13,503
Imbruvica38$429,346$11,299
Calquence25$380,497$15,220
Alecensa18$333,171$18,510
Tagrisso18$328,498$18,250
Tasigna16$323,265$20,204
Verzenio20$304,382$15,219
Abiraterone Acetate50$219,911$4,398
Lynparza15$176,334$11,756
Gleevec11$125,002$11,364
Eliquis66$47,555$721
Imatinib Mesylate21$43,962$2,093
Xarelto27$16,897$626
Letrozole208$12,340$59
Exemestane21$4,785$228
Potassium Chloride87$2,091$24
Hydrocodone-Acetaminophen56$1,864$33
Prochlorperazine Maleate104$1,164$11
Acyclovir74$1,123$15
Anastrozole31$1,051$34
Oxycodone35$1,045$30
Tamoxifen Citrate58$1,006$17
Hydroxyurea44$996$23
Lorazepam95$886$9
Ondansetron54$642$12
Dexamethasone55$599$11
Prednisone90$587$7
Levothyroxine47$426$9
Methadone16$424$26
Ondansetron Odt29$409$14
Mirtazapine14$398$28
Diphenoxylate-Atropine21$390$19
Gabapentin28$362$13
Omeprazole15$325$22
Albuterol Sulfate Hfa11$311$28
Olanzapine38$298$8
Nystatin11$262$24
Klor-Con 1022$259$12
Tramadol40$257$6
Warfarin12$96$8
Citalopram Hbr26$94$4
Diazepam15$62$4
Zolpidem16$43$3

2022: 41 drugs

Part D drugs prescribed in 2022
Revlimid121$2,385,413$19,714
Ibrance49$651,681$13,300
Imbruvica52$592,345$11,391
Jakafi30$449,361$14,979
Tagrisso22$364,956$16,589
Alecensa20$350,176$17,509
Tepmetko11$244,052$22,187
Abiraterone Acetate43$243,001$5,651
Calquence18$235,318$13,073
Deferasirox15$55,769$3,718
Imatinib Mesylate13$48,679$3,745
Eliquis56$44,796$800
Xarelto39$28,023$719
Letrozole140$6,059$43
Exemestane17$4,447$262
Oxycodone41$2,064$50
Ondansetron51$1,291$25
Acyclovir74$1,261$17
Ondansetron Odt52$1,139$22
Potassium Chloride68$1,058$16
Hydroxyurea32$1,046$33
Hydrocodone-Acetaminophen42$948$23
Prochlorperazine Maleate80$908$11
Tamoxifen Citrate27$755$28
Morphine Sulfate Er16$733$46
Gabapentin43$710$17
Dexamethasone53$681$13
Anastrozole25$567$23
Lorazepam93$487$5
Prednisone58$476$8
Olanzapine16$417$26
Omeprazole32$414$13
Methadone16$285$18
Levothyroxine19$189$10
Zolpidem27$171$6
Pantoprazole18$158$9
Mirtazapine15$138$9
Tramadol15$117$8
Citalopram Hbr23$74$3
Diazepam13$56$4
Furosemide15$43$3

2021: 43 drugs

Part D drugs prescribed in 2021
Revlimid118$2,136,074$18,102
Ibrance87$1,143,091$13,139
Imbruvica72$843,088$11,710
Tagrisso19$312,777$16,462
Abiraterone Acetate53$261,313$4,930
Alecensa13$214,828$16,525
Lynparza13$192,731$14,825
Creon17$47,135$2,773
Eliquis64$39,464$617
Xarelto26$19,574$753
Exemestane28$8,790$314
Imatinib Mesylate12$6,348$529
Letrozole184$5,129$28
Acyclovir108$2,159$20
Hydroxyurea46$1,779$39
Dexamethasone68$1,640$24
Tamoxifen Citrate35$1,580$45
Hydrocodone-Acetaminophen47$1,357$29
Diphenoxylate-Atropine22$1,255$57
Potassium Chloride49$1,153$24
Oxycodone35$1,124$32
Ondansetron65$1,122$17
Prochlorperazine Maleate66$1,022$15
Morphine Sulfate Er12$989$82
Anastrozole37$969$26
Ondansetron Odt45$722$16
Gabapentin61$709$12
Valacyclovir15$613$41
Omeprazole65$612$9
Oxycodone-Acetaminophen14$520$37
Prednisone56$491$9
Lorazepam64$452$7
Levothyroxine36$417$12
Levetiracetam12$306$26
Acetaminophen-Codeine12$297$25
Lidocaine-Prilocaine12$154$13
Zolpidem22$146$7
Lisinopril20$123$6
Tramadol15$118$8
Sulfamethoxazole-Trimethoprim18$96$5
Diazepam11$52$5
Warfarin13$50$4
Furosemide11$50$5

2020: 46 drugs

Part D drugs prescribed in 2020
Revlimid104$1,780,436$17,120
Ibrance65$909,980$14,000
Imbruvica49$595,252$12,148
Pomalyst15$305,069$20,338
Afinitor11$194,875$17,716
Tagrisso12$193,651$16,138
Zytiga11$116,111$10,556
Eliquis71$41,910$590
Abiraterone Acetate13$26,468$2,036
Xarelto24$20,830$868
Fondaparinux12$15,956$1,330
Exemestane24$7,140$297
Letrozole230$5,994$26
Tamoxifen Citrate53$3,007$57
Acyclovir88$2,416$27
Dexamethasone59$1,799$30
Hydroxyurea43$1,720$40
Oxycodone39$1,392$36
Oxycodone-Acetaminophen26$1,284$49
Valacyclovir19$1,148$60
Potassium Chloride42$1,049$25
Methylprednisolone13$1,027$79
Morphine Sulfate Er11$971$88
Ondansetron Odt43$876$20
Anastrozole33$834$25
Prochlorperazine Maleate56$783$14
Hydrocodone-Acetaminophen36$730$20
Omeprazole40$683$17
Prednisone70$612$9
Diphenoxylate-Atropine22$606$28
Pregabalin12$605$50
Ondansetron40$598$15
Levothyroxine32$450$14
Lorazepam71$417$6
Tramadol12$349$29
Klor-Con 1013$322$25
Gabapentin26$208$8
Lidocaine-Prilocaine11$189$17
Warfarin18$185$10
Citalopram Hbr26$182$7
Acetaminophen-Codeine11$155$14
Zolpidem14$151$11
Alendronate14$119$9
Furosemide24$95$4
Lisinopril18$74$4
Sulfamethoxazole-Trimethoprim12$39$3

2019: 46 drugs

Part D drugs prescribed in 2019
Revlimid73$1,167,277$15,990
Ibrance51$632,789$12,408
Zytiga44$486,011$11,046
Imbruvica39$419,580$10,758
Tagrisso15$225,643$15,043
Afinitor11$182,123$16,557
Ninlaro15$155,797$10,386
Abiraterone Acetate25$131,409$5,256
Eliquis102$54,082$530
Creon14$36,234$2,588
Fondaparinux13$30,148$2,319
Xarelto34$21,519$633
Letrozole241$6,312$26
Exemestane13$5,181$399
Tamoxifen Citrate62$2,732$44
Oxycodone33$1,742$53
Hydrocodone-Acetaminophen42$1,550$37
Potassium Chloride55$1,311$24
Hydroxyurea48$1,116$23
Acyclovir68$1,063$16
Methylprednisolone14$1,049$75
Anastrozole37$979$26
Dexamethasone49$884$18
Oxycodone-Acetaminophen20$816$41
Morphine Sulfate Er14$797$57
Prednisone76$769$10
Ondansetron Odt33$753$23
Levothyroxine30$484$16
Mirtazapine22$483$22
Prochlorperazine Maleate47$436$9
Lorazepam78$403$5
Gabapentin26$366$14
Diphenoxylate-Atropine13$337$26
Ondansetron29$335$12
Ranitidine13$262$20
Valacyclovir11$230$21
Omeprazole29$219$8
Sumatriptan12$187$16
Venlafaxine Hcl Er11$177$16
Zolpidem21$159$8
Tramadol18$112$6
Citalopram Hbr31$86$3
Tamsulosin19$80$4
Sulfamethoxazole-Trimethoprim14$77$5
Furosemide19$46$2
Lisinopril11$44$4

2018: 46 drugs

Part D drugs prescribed in 2018
Revlimid44$707,540$16,080
Zytiga42$432,763$10,304
Ibrance29$344,633$11,884
Gleevec22$223,971$10,181
Alecensa11$172,423$15,675
Verzenio15$166,584$11,106
Imbruvica14$150,805$10,772
Xtandi14$116,432$8,317
Eliquis81$41,496$512
Creon14$40,618$2,901
Xarelto31$14,919$481
Letrozole295$5,765$20
Tamoxifen Citrate86$2,778$32
Ondansetron Odt50$1,500$30
Hydrocodone-Acetaminophen46$1,327$29
Oxycodone28$1,257$45
Methylprednisolone12$1,062$89
Anastrozole40$935$23
Oxycodone-Acetaminophen15$835$56
Hydroxyurea38$737$19
Klor-Con 1012$652$54
Morphine Sulfate15$644$43
Potassium Chloride27$613$23
Acyclovir45$613$14
Lorazepam111$582$5
Diphenoxylate-Atropine13$544$42
Prednisone57$494$9
Prochlorperazine Maleate63$482$8
Omeprazole54$469$9
Levothyroxine40$428$11
Methadone13$395$30
Dexamethasone28$386$14
Ondansetron29$310$11
Lidocaine-Prilocaine17$293$17
Valacyclovir12$289$24
Tamsulosin20$257$13
Zolpidem30$241$8
Temazepam25$212$8
Gabapentin17$196$12
Mirtazapine11$196$18
Sumatriptan13$157$12
Trazodone12$153$13
Tramadol11$127$12
Ibuprofen11$64$6
Citalopram Hbr11$54$5
Lisinopril19$49$3

2017: 38 drugs

Part D drugs prescribed in 2017
Revlimid50$660,884$13,218
Zytiga32$289,035$9,032
Imbruvica26$254,369$9,783
Ibrance20$226,083$11,304
Pomalyst15$223,863$14,924
Gleevec19$194,410$10,232
Afinitor12$161,300$13,442
Alecensa11$158,188$14,381
Eliquis42$17,563$418
Xarelto21$9,659$460
Exemestane19$5,526$291
Letrozole255$5,361$21
Tamoxifen Citrate64$1,963$31
Anastrozole37$775$21
Hydroxyurea38$763$20
Acyclovir53$727$14
Ondansetron Odt41$678$17
Morphine Sulfate Er14$650$46
Hydrocodone-Acetaminophen29$543$19
Levothyroxine41$510$12
Prednisone69$501$7
Omeprazole53$458$9
Dexamethasone29$451$16
Morphine Sulfate17$438$26
Oxycodone11$410$37
Nystatin11$396$36
Lorazepam77$392$5
Gabapentin16$366$23
Zolpidem43$314$7
Prochlorperazine Maleate54$287$5
Lidocaine-Prilocaine11$275$25
Ondansetron25$262$10
Valacyclovir11$243$22
Klor-Con Sprinkle13$217$17
Spironolactone12$135$11
Alendronate12$127$11
Pantoprazole13$106$8
Citalopram Hbr12$54$4

2016: 41 drugs

Part D drugs prescribed in 2016
Gleevec22$224,553$10,207
Xalkori15$222,234$14,816
Revlimid19$219,192$11,536
Pomalyst11$148,755$13,523
Ibrance14$146,403$10,457
Xtandi15$123,859$8,257
Imbruvica11$107,794$9,799
Zytiga12$99,377$8,281
Xarelto19$6,751$355
Letrozole209$4,068$19
Exemestane19$3,852$203
Enoxaparin11$3,686$335
Hydrocodone-Acetaminophen56$1,969$35
Tamoxifen Citrate57$1,385$24
Fentanyl15$1,317$88
Oxycodone30$1,275$42
Lorazepam90$706$8
Ondansetron Odt46$584$13
Anastrozole31$532$17
Prochlorperazine Maleate74$505$7
Hydroxyurea29$501$17
Morphine Sulfate15$491$33
Dexamethasone33$426$13
Omeprazole60$414$7
Gabapentin24$399$17
Zolpidem43$378$9
Lidocaine-Prilocaine11$334$30
Nystatin12$302$25
Acyclovir17$285$17
Prednisone28$241$9
Pravastatin12$236$20
Potassium Chloride14$226$16
Levothyroxine18$203$11
Bicalutamide11$162$15
Ondansetron20$141$7
Naproxen12$109$9
Sulfamethoxazole-Trimethoprim16$87$5
Alprazolam12$51$4
Hydrochlorothiazide17$47$3
Fluoxetine11$33$3
Amlodipine Besylate13$23$2

2015: 34 drugs

Part D drugs prescribed in 2015
Revlimid27$294,758$10,917
Gleevec19$185,875$9,783
Xalkori11$152,525$13,866
Xtandi13$111,205$8,554
Imbruvica11$99,789$9,072
Tarceva13$77,660$5,974
Exemestane27$6,833$253
Xarelto11$5,539$504
Letrozole238$3,321$14
Oxycontin11$2,359$214
Oxycodone39$1,609$41
Hydrocodone-Acetaminophen61$1,538$25
Tamoxifen Citrate38$1,185$31
Anastrozole88$969$11
Lorazepam110$900$8
Morphine Sulfate Er16$880$55
Ondansetron Odt31$728$23
Omeprazole74$508$7
Hydroxyurea34$418$12
Dexamethasone34$361$11
Zolpidem21$357$17
Gabapentin24$340$14
Prochlorperazine Maleate48$260$5
Tamsulosin11$251$23
Prednisone30$243$8
Bicalutamide16$224$14
Ondansetron15$210$14
Tramadol21$139$7
Lisinopril17$131$8
Acyclovir12$105$9
Hydromorphone12$101$8
Ciprofloxacin12$51$4
Sulfamethoxazole-Trimethoprim12$44$4
Furosemide12$39$3

2014: 29 drugs

Part D drugs prescribed in 2014
Revlimid22$211,835$9,629
Gleevec20$167,075$8,354
Xtandi18$164,018$9,112
Tarceva23$134,396$5,843
Exemestane24$6,439$268
Xarelto16$5,707$357
Letrozole257$4,285$17
Celebrex13$2,691$207
Hydrocodone-Acetaminophen75$2,237$30
Anastrozole93$1,537$17
Oxycodone24$1,070$45
Lorazepam134$983$7
Morphine Sulfate Er12$945$79
Hydroxyurea26$701$27
Tamoxifen Citrate29$603$21
Prochlorperazine Maleate51$447$9
Potassium Chloride17$414$24
Ondansetron Odt16$385$24
Dexamethasone39$370$9
Prednisone33$298$9
Omeprazole32$240$8
Escitalopram12$229$19
Tamsulosin16$213$13
Zolpidem26$209$8
Minocycline11$188$17
Tramadol14$143$10
Ondansetron11$122$11
Lisinopril11$90$8
Furosemide18$67$4

2013: 34 drugs

Part D drugs prescribed in 2013
Tarceva33$178,412$5,406
Revlimid16$151,672$9,480
Xtandi12$137,865$11,489
Gleevec20$134,251$6,713
Xalkori12$132,498$11,041
Zytiga12$79,345$6,612
Enoxaparin11$15,157$1,378
Exemestane45$9,748$217
Letrozole192$4,556$24
Celebrex11$4,226$384
Anastrozole80$2,661$33
Hydrocodone-Acetaminophen105$2,256$21
Fentanyl12$1,923$160
Bicalutamide16$1,161$73
Oxycodone25$1,080$43
Tamoxifen Citrate38$741$20
Megestrol Acetate15$727$48
Lorazepam104$707$7
Morphine Sulfate Er12$524$44
Potassium Chloride12$410$34
Omeprazole34$290$9
Tamsulosin13$244$19
Prochlorperazine Maleate31$223$7
Ondansetron12$218$18
Benazepril16$213$13
Ropinirole11$206$19
Zolpidem27$192$7
Warfarin18$174$10
Alendronate12$125$10
Dexamethasone11$113$10
Temazepam14$111$8
Tramadol11$87$8
Furosemide15$83$6
Prednisone16$79$5

Money from drug and device companies

$778 in 2025

Industry payments by year
20251530None$778
20241522None$604
20231020None$531
20222250$937$1,898
20211966None$1,859
20202141None$1,111
20192783None$1,386

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Daiichi SankyoEnhertu$161
7 payments
  • Meals for Datroway · 2025-12-09 · $19
  • Meals for Enhertu · 2025-12-05 · $29
  • Meals for Enhertu · 2025-11-18 · $28
  • Meals for Enhertu · 2025-10-22 · $27
  • Meals for Datroway · 2025-08-21 · $26
  • Meals for Datroway · 2025-08-19 · $25
  • Meals for Enhertu · 2025-06-18 · $7
AstraZeneca Pharmaceuticals LPEnhertu$89
4 payments
  • Meals for Lynparza · 2025-12-30 · $25
  • Meals for Enhertu · 2025-10-21 · $24
  • Meals for Enhertu · 2025-09-26 · $21
  • Meals for Enhertu · 2025-04-15 · $19
Regeneron PharmaceuticalsLynozyfic$80
2 payments
  • Meals for Lynozyfic · 2025-11-11 · $38
  • Meals for Lynozyfic · 2025-08-31 · $41
Gilead SciencesTrodelvy$67
3 payments
  • Meals for Trodelvy · 2025-11-11 · $25
  • Meals for Trodelvy · 2025-07-22 · $22
  • Meals for Trodelvy · 2025-02-27 · $21
Takeda Pharmaceuticals U.S.A.Iclusig$62
3 payments
  • Meals for Iclusig · 2025-11-04 · $19
  • Meals for Iclusig · 2025-04-24 · $22
  • Meals for Ninlaro · 2025-02-04 · $21
EMD SeronoNone$56
1 payment
  • Education · 2025-06-13 · $56
See all 30 published payments
Every published payment
AstraZeneca Pharmaceuticals LPMeals · 2025-12-30Lynparza$25
Genentech USAMeals · 2025-12-16Itovebi$21
Daiichi SankyoMeals · 2025-12-09Datroway$19
Daiichi SankyoMeals · 2025-12-05Enhertu$29
Daiichi SankyoMeals · 2025-11-18Enhertu$28
Regeneron PharmaceuticalsMeals · 2025-11-11Lynozyfic$38
Gilead SciencesMeals · 2025-11-11Trodelvy$25
Takeda Pharmaceuticals U.S.A.Meals · 2025-11-04Iclusig$19
Daiichi SankyoMeals · 2025-10-22Enhertu$27
AstraZeneca Pharmaceuticals LPMeals · 2025-10-21Enhertu$24
Merck Sharp & DohmeMeals · 2025-10-17Keytruda$33
Bayer Healthcare PharmaceuticalsMeals · 2025-10-14Nubeqa$20
AstraZeneca Pharmaceuticals LPMeals · 2025-09-26Enhertu$21
Ipsen BiopharmaceuticalsMeals · 2025-09-12Onivyde$32
Regeneron PharmaceuticalsMeals · 2025-08-31Lynozyfic$41
Daiichi SankyoMeals · 2025-08-21Datroway$26
Daiichi SankyoMeals · 2025-08-19Datroway$25
Boehringer Ingelheim PharmaceuticalsMeals · 2025-07-31None$25
Gilead SciencesMeals · 2025-07-22Trodelvy$22
Daiichi SankyoMeals · 2025-06-18Enhertu$7
EMD SeronoEducation · 2025-06-13None$56
Rigel PharmaceuticalsMeals · 2025-05-08Tavalisse$27
Takeda Pharmaceuticals U.S.A.Meals · 2025-04-24Iclusig$22
AstraZeneca Pharmaceuticals LPMeals · 2025-04-15Enhertu$19
Genentech USAMeals · 2025-04-08Tecentriq Hybreza$33
Stemline TherapeuticsMeals · 2025-04-07Orserdu$20
Array BiopharmaMeals · 2025-03-25Braftovi$23
AbbvieMeals · 2025-03-21None$28
Gilead SciencesMeals · 2025-02-27Trodelvy$21
Takeda Pharmaceuticals U.S.A.Meals · 2025-02-04Ninlaro$21
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $604

Payments by company in 2024
PfizerIbrance$85
4 payments
  • Meals for Ibrance · 2024-09-20 · $7
  • Meals for Ibrance · 2024-07-09 · $31
  • Meals for Xtandi · 2024-04-24 · $17
  • Meals for Padcev · 2024-04-09 · $31
Lilly USAJaypirca$64
2 payments
  • Meals for Verzenio · 2024-10-17 · $32
  • Meals for Jaypirca · 2024-08-22 · $33
SpringWorks TherapeuticsOgsiveo$64
2 payments
  • Meals for Ogsiveo · 2024-06-12 · $27
  • Meals for Ogsiveo · 2024-02-14 · $37
AbbvieImbruvica$62
2 payments
  • Meals for Imbruvica · 2024-09-10 · $27
  • Meals · 2024-07-11 · $35
Stemline TherapeuticsOrserdu$43
1 payment
  • Meals for Orserdu · 2024-12-17 · $43
Janssen BiotechDarzalex$36
1 payment
  • Meals for Darzalex · 2024-12-04 · $36
Array BiopharmaLorbrena$35
1 payment
  • Meals for Lorbrena · 2024-10-15 · $35
Daiichi SankyoEnhertu$34
2 payments
  • Meals for Enhertu · 2024-08-15 · $20
  • Meals for Enhertu · 2024-07-23 · $14
Merck Sharp & DohmeKeytruda$32
1 payment
  • Meals for Keytruda · 2024-12-17 · $32
Novartis PharmaceuticalsScemblix$30
1 payment
  • Meals for Scemblix · 2024-05-15 · $30
CelgeneReblozyl$30
1 payment
  • Meals for Reblozyl · 2024-05-01 · $30
AstraZeneca Pharmaceuticals LPEnhertu$28
1 payment
  • Meals for Enhertu · 2024-11-08 · $28
GlaxoSmithKlineOjjaara$23
1 payment
  • Meals for Ojjaara · 2024-01-23 · $23
Genmab U.S.Epkinly$23
1 payment
  • Meals for Epkinly · 2024-09-27 · $23
Gilead SciencesNone$14
1 payment
  • Meals · 2024-02-28 · $14

2023: $531

Payments by company in 2023
Progenics PharmaceuticalsPylarify$150
1 payment
  • Meals for Pylarify · 2023-02-08 · $150
PfizerIbrance$114
6 payments
  • Education for Ibrance · 2023-09-26 · $25
  • Education for Ibrance · 2023-09-21 · $25
  • Meals for Ibrance · 2023-08-23 · $25
  • Education for Inlyta · 2023-05-23 · $7
  • Education for Ibrance · 2023-04-27 · $32
  • Meals for Ibrance · 2023-03-21 · $1
GlaxoSmithKlineJemperli$53
2 payments
  • Meals for Jemperli · 2023-10-23 · $29
  • Meals for Zejula · 2023-08-11 · $24
Novartis PharmaceuticalsPiqray$41
2 payments
  • Meals · 2023-11-14 · $19
  • Meals for Piqray · 2023-09-19 · $21
Alexion PharmaceuticalsUltomiris$39
2 payments
  • Meals for Ultomiris · 2023-06-20 · $14
  • Meals for Ultomiris · 2023-02-21 · $25
Mirati TherapeuticsKrazati$37
2 payments
  • Meals for Krazati · 2023-06-13 · $14
  • Meals for Krazati · 2023-01-30 · $23
GE HealthCareNone$26
2 payments
  • Meals · 2023-09-12 · $24
  • Meals · 2023-09-12 · $2
BeiGene USABrukinsa$25
1 payment
  • Meals for Brukinsa · 2023-02-15 · $25
SeagenPadcev$25
1 payment
  • Meals for Padcev · 2023-11-07 · $25
CelgenePomalyst$20
1 payment
  • Meals for Pomalyst · 2023-07-18 · $20

2022: $1,898

Payments by company in 2022
EMD SeronoNone$937
7 payments
  • Paid to speak or teach · 2022-11-01 · $24
  • Paid to speak or teach · 2022-11-01 · $135
  • Paid to speak or teach · 2022-11-01 · $265
  • Paid to speak or teach · 2022-09-01 · $127
  • Paid to speak or teach · 2022-08-01 · $281
  • Paid to speak or teach · 2022-08-01 · $10
  • Paid to speak or teach · 2022-04-01 · $94
CelgenePomalyst$118
6 payments
  • Meals for Pomalyst · 2022-10-04 · $20
  • Meals for Pomalyst · 2022-07-25 · $17
  • Meals for Reblozyl · 2022-07-15 · $26
  • Meals for Pomalyst · 2022-05-10 · $18
  • Meals for Reblozyl · 2022-04-25 · $22
  • Meals for Pomalyst · 2022-03-09 · $16
Taiho OncologyInqovi$93
1 payment
  • Meals for Inqovi · 2022-05-24 · $93
GlaxoSmithKlineZejula$91
5 payments
  • Meals for Zejula · 2022-05-10 · $14
  • Meals for Zejula · 2022-03-22 · $13
  • Meals for Zejula · 2022-03-10 · $35
  • Meals for Zejula · 2022-02-15 · $14
  • Meals for Zejula · 2022-01-13 · $16
Pharmacyclics LLC an AbbVieImbruvica$88
3 payments
  • Meals for Imbruvica · 2022-11-29 · $29
  • Meals for Imbruvica · 2022-07-08 · $30
  • Meals for Imbruvica · 2022-04-15 · $29
Novartis PharmaceuticalsAdakveo$82
4 payments
  • Meals for Scemblix · 2022-10-25 · $22
  • Meals for Adakveo · 2022-06-14 · $22
  • Meals · 2022-04-08 · $19
  • Meals · 2022-02-15 · $20
Janssen BiotechErleada$78
5 payments
  • Meals for Erleada · 2022-07-12 · $16
  • Meals for Erleada · 2022-06-17 · $19
  • Meals for Rybrevant · 2022-06-13 · $17
  • Meals for Darzalex · 2022-05-17 · $12
  • Meals for Imbruvica · 2022-03-31 · $15
E.R. Squibb & Sons L.L.C.Opdivo$53
2 payments
  • Meals for Opdivo · 2022-09-27 · $33
  • Meals for Opdivo · 2022-07-01 · $20
SeagenPadcev$45
2 payments
  • Meals for Padcev · 2022-04-29 · $18
  • Meals for Padcev · 2022-02-01 · $27
Gilead SciencesTrodelvy$39
2 payments
  • Meals for Trodelvy · 2022-07-30 · $13
  • Meals for Trodelvy · 2022-01-11 · $26
Astellas Pharma USXtandi$37
2 payments
  • Meals for Padcev · 2022-09-15 · $14
  • Meals for Xtandi · 2022-06-16 · $23
Regeneron Healthcare SolutionsLibtayo$30
1 payment
  • Meals for Libtayo · 2022-06-30 · $30
Servier PharmaceuticalsTibsovo$23
1 payment
  • Meals for Tibsovo · 2022-08-31 · $23
AstraZeneca Pharmaceuticals LPNone$23
1 payment
  • Meals · 2022-11-18 · $23
Jazz PharmaceuticalsZepzelca$23
1 payment
  • Meals for Zepzelca · 2022-10-24 · $23
Alexion PharmaceuticalsUltomiris$23
1 payment
  • Meals for Ultomiris · 2022-03-29 · $23
Genentech USAVenclexta$22
1 payment
  • Meals for Venclexta · 2022-05-27 · $22
ADC Therapeutics AmericaNone$22
1 payment
  • Meals · 2022-03-28 · $22
Merck Sharp & DohmeKeytruda$21
1 payment
  • Meals for Keytruda · 2022-04-28 · $21
TerSera TherapeuticsXermelo$18
1 payment
  • Meals for Xermelo · 2022-07-20 · $18
Kite PharmaNone$16
1 payment
  • Meals · 2022-04-11 · $16
Kyowa KirinPoteligeo$15
1 payment
  • Meals for Poteligeo · 2022-04-26 · $15

2021: $1,859

Payments by company in 2021
EMD SeronoNone$644
5 payments
  • Education · 2021-12-01 · $133
  • Education · 2021-12-01 · $4
  • Education · 2021-12-01 · $374
  • Education · 2021-08-02 · $119
  • Meals · 2021-04-16 · $14
GlaxoSmithKlineZejula$261
11 payments
  • Meals for Zejula · 2021-12-14 · $32
  • Meals for Zejula · 2021-11-11 · $34
  • Meals for Zejula · 2021-09-28 · $19
  • Meals for Zejula · 2021-09-02 · $30
  • Meals for Blenrep · 2021-07-23 · $35
  • Meals for Zejula · 2021-07-22 · $26
  • Meals for Zejula · 2021-07-22 · $21
  • Meals for Zejula · 2021-06-14 · $10
  • Meals for Zejula · 2021-04-22 · $26
  • Meals for Zejula · 2021-03-30 · $15
  • Meals for Zejula · 2021-02-17 · $13
Pharmacyclics LLC An AbbVieImbruvica$190
10 payments
  • Meals for Imbruvica · 2021-12-16 · $29
  • Meals for Imbruvica · 2021-10-07 · $27
  • Meals for Imbruvica · 2021-07-20 · $3
  • Meals for Imbruvica · 2021-07-20 · $17
  • Meals for Imbruvica · 2021-07-16 · $8
  • Meals for Imbruvica · 2021-06-15 · $27
  • Meals for Imbruvica · 2021-05-04 · $20
  • Meals for Imbruvica · 2021-04-23 · $8
  • Meals for Imbruvica · 2021-04-05 · $30
  • Meals for Imbruvica · 2021-01-26 · $21
Novartis PharmaceuticalsTasigna$122
7 payments
  • Meals for Scemblix · 2021-11-09 · $18
  • Meals for Tasigna · 2021-08-31 · $19
  • Meals for Tabrecta · 2021-08-31 · $2
  • Meals for Lutathera · 2021-08-05 · $22
  • Meals for Tasigna · 2021-07-16 · $23
  • Meals for Lutathera · 2021-06-04 · $20
  • Meals for Tabrecta · 2021-04-20 · $19
Merck Sharp & DohmeKeytruda$90
4 payments
  • Meals for Keytruda · 2021-10-22 · $19
  • Meals for Keytruda · 2021-08-27 · $24
  • Meals for Keytruda · 2021-04-29 · $22
  • Meals for Keytruda · 2021-04-21 · $25
SeagenTukysa$85
3 payments
  • Meals for Padcev · 2021-07-27 · $31
  • Meals for Tukysa · 2021-04-09 · $24
  • Meals for Tukysa · 2021-02-02 · $31
PfizerIbrance$68
5 payments
  • Education for Ibrance · 2021-09-28 · $13
  • Education for Ibrance · 2021-09-16 · $13
  • Meals for Ibrance · 2021-08-03 · $16
  • Meals for Ibrance · 2021-05-18 · $13
  • Education for Inlyta · 2021-03-24 · $13
Janssen BiotechErleada$66
4 payments
  • Meals for Erleada · 2021-12-07 · $25
  • Meals for Erleada · 2021-11-19 · $14
  • Meals for Imbruvica · 2021-09-28 · $16
  • Meals for Darzalex · 2021-06-23 · $11
EisaiLenvima$62
3 payments
  • Meals for Lenvima · 2021-12-09 · $25
  • Meals for Lenvima · 2021-06-30 · $23
  • Meals for Lenvima · 2021-05-20 · $14
Alexion PharmaceuticalsUltomiris$43
2 payments
  • Meals for Ultomiris · 2021-12-21 · $25
  • Meals for Ultomiris · 2021-04-02 · $19
AmgenLumakras$41
2 payments
  • Meals for Lumakras · 2021-11-02 · $25
  • Meals for Nplate · 2021-06-15 · $15
CelgenePomalyst$37
2 payments
  • Meals for Pomalyst · 2021-09-21 · $21
  • Meals for Pomalyst · 2021-09-16 · $16
Gilead SciencesTrodelvy$37
2 payments
  • Education · 2021-06-01 · $12
  • Meals for Trodelvy · 2021-04-20 · $25
AstraZeneca Pharmaceuticals LPTagrisso$24
1 payment
  • Meals for Tagrisso · 2021-01-29 · $24
BeiGene USABrukinsa$20
1 payment
  • Meals for Brukinsa · 2021-04-13 · $20
Takeda Pharmaceuticals U.S.A.Alunbrig$18
1 payment
  • Meals for Alunbrig · 2021-04-06 · $18
Jazz PharmaceuticalsZepzelca$18
1 payment
  • Meals for Zepzelca · 2021-09-28 · $18
Astellas Pharma USXtandi$17
1 payment
  • Meals for Xtandi · 2021-06-24 · $17
Taiho OncologyLonsurf$15
1 payment
  • Meals for Lonsurf · 2021-06-18 · $15

2020: $1,111

Payments by company in 2020
PfizerLorbrena$454
6 payments
  • Education for Lorbrena · 2020-11-05 · $119
  • Education for Lorbrena · 2020-11-05 · $81
  • Meals for Ibrance · 2020-08-20 · $13
  • Education for Inlyta · 2020-08-19 · $133
  • Education for Lorbrena · 2020-07-28 · $81
  • Meals for Lorbrena · 2020-07-24 · $28
E.R. Squibb & Sons L.L.C.Opdivo$127
8 payments
  • Meals for Opdivo · 2020-09-25 · $20
  • Meals · 2020-08-18 · $10
  • Meals for Opdivo · 2020-07-29 · $16
  • Meals for Inrebic · 2020-06-05 · $10
  • Meals for Opdivo · 2020-05-19 · $13
  • Meals · 2020-03-12 · $21
  • Meals for Opdivo · 2020-02-07 · $17
  • Meals · 2020-01-09 · $19
Pharmacyclics LLC An AbbVieImbruvica$88
1 payment
  • Education for Imbruvica · 2020-07-17 · $88
Merck Sharp & DohmeKeytruda$69
4 payments
  • Meals for Keytruda · 2020-11-05 · $16
  • Meals for Keytruda · 2020-10-20 · $14
  • Meals for Keytruda · 2020-09-08 · $19
  • Meals for Keytruda · 2020-03-05 · $19
SeagenPadcev$49
3 payments
  • Meals for Padcev · 2020-09-29 · $17
  • Meals for Padcev · 2020-08-18 · $14
  • Meals for Adcetris · 2020-01-09 · $17
AmgenKyprolis$39
2 payments
  • Meals for Kyprolis · 2020-09-11 · $18
  • Meals for Kyprolis · 2020-01-21 · $21
Agios PharmaceuticalsTibsovo$38
2 payments
  • Meals for Tibsovo · 2020-02-25 · $23
  • Meals for Tibsovo · 2020-02-12 · $15
Janssen BiotechDarzalex$25
2 payments
  • Meals for Darzalex · 2020-05-11 · $12
  • Meals for Darzalex · 2020-01-31 · $13
Genentech USAKadcyla$20
1 payment
  • Meals for Kadcyla · 2020-09-10 · $20
ExelixisCabometyx$19
1 payment
  • Meals for Cabometyx · 2020-10-21 · $19
Clovis OncologyRubraca$19
1 payment
  • Meals for Rubraca · 2020-02-27 · $19
Taiho OncologyNone$19
1 payment
  • Meals · 2020-11-04 · $19
CelgeneReblozyl$19
1 payment
  • Meals for Reblozyl · 2020-06-04 · $19
Boehringer Ingelheim PharmaceuticalsGilotrif$18
1 payment
  • Meals for Gilotrif · 2020-02-13 · $18
Karyopharm TherapeuticsXpovio$17
1 payment
  • Meals for Xpovio · 2020-01-31 · $17
EisaiLenvima$17
1 payment
  • Meals for Lenvima · 2020-02-29 · $17
Jazz PharmaceuticalsZepzelca$17
1 payment
  • Meals for Zepzelca · 2020-10-06 · $17
Daiichi SankyoEnhertu$16
1 payment
  • Meals for Enhertu · 2020-02-04 · $16
GenzymeJevtana$16
1 payment
  • Meals for Jevtana · 2020-12-15 · $16
GlaxoSmithKlineZejula$14
1 payment
  • Meals for Zejula · 2020-08-13 · $14
AstraZeneca Pharmaceuticals LPTagrisso$11
1 payment
  • Meals for Tagrisso · 2020-02-14 · $11

2019: $1,386

Payments by company in 2019
E.R. Squibb & Sons L.L.C.Empliciti$178
14 payments
  • Meals · 2019-12-17 · $10
  • Meals · 2019-12-17 · $1
  • Meals · 2019-11-22 · $18
  • Meals · 2019-11-06 · $18
  • Meals · 2019-10-03 · $20
  • Meals · 2019-10-03 · $1
  • Meals · 2019-09-18 · $17
  • Meals for Eliquis · 2019-08-29 · $25
  • Meals for Empliciti · 2019-07-29 · $18
  • Meals for Empliciti · 2019-04-19 · $1
  • Meals for Empliciti · 2019-04-19 · $21
  • Meals · 2019-04-02 · $12
  • Meals for Empliciti · 2019-03-14 · $16
  • Meals for Empliciti · 2019-03-14 · $1
PfizerXtandi$148
12 payments
  • Education for Braftovi · 2019-11-04 · $13
  • Meals for Bavencio · 2019-10-22 · $13
  • Education for Bavencio · 2019-10-21 · $15
  • Education for Lorbrena · 2019-10-21 · $8
  • Education for Lorbrena · 2019-10-21 · $11
  • Meals for Xtandi · 2019-10-09 · $30
  • Meals for Xtandi · 2019-07-26 · $19
  • Education for Bosulif · 2019-06-20 · $1
  • Meals for Xtandi · 2019-03-22 · $20
  • Education for Bosulif · 2019-03-04 · $8
  • Meals for Mylotarg · 2019-01-18 · $10
  • Meals for Mylotarg · 2019-01-18 · $0
AstraZeneca Pharmaceuticals LPImfinzi$112
8 payments
  • Meals for Tagrisso · 2019-11-12 · $20
  • Meals for Imfinzi · 2019-09-26 · $22
  • Meals for Imfinzi · 2019-06-19 · $1
  • Meals for Lynparza · 2019-06-19 · $17
  • Meals for Imfinzi · 2019-04-05 · $22
  • Meals · 2019-03-21 · $14
  • Meals for Lynparza · 2019-02-07 · $15
  • Meals for Lynparza · 2019-02-06 · $1
Genentech USAPerjeta$107
5 payments
  • Meals for Perjeta · 2019-12-06 · $20
  • Meals for Tecentriq · 2019-09-09 · $20
  • Meals for Perjeta · 2019-05-16 · $24
  • Meals for Venclexta · 2019-04-12 · $20
  • Meals for Tecentriq · 2019-04-11 · $23
Merck Sharp & DohmeKeytruda$103
6 payments
  • Meals for Keytruda · 2019-12-12 · $17
  • Meals for Keytruda · 2019-11-15 · $18
  • Meals for Keytruda · 2019-08-13 · $14
  • Meals for Keytruda · 2019-08-01 · $18
  • Meals for Lynparza · 2019-07-18 · $16
  • Meals for Keytruda · 2019-06-20 · $20
CelgeneRevlimid$66
3 payments
  • Meals for Inrebic · 2019-11-21 · $17
  • Meals for Revlimid · 2019-09-05 · $24
  • Meals for Revlimid · 2019-08-20 · $24
Rigel PharmaceuticalsTavalisse$63
3 payments
  • Meals for Tavalisse · 2019-12-17 · $23
  • Meals for Tavalisse · 2019-12-17 · $23
  • Meals for Tavalisse · 2019-09-22 · $17
Clovis OncologyRubraca$59
4 payments
  • Meals for Rubraca · 2019-11-05 · $22
  • Meals for Rubraca · 2019-06-11 · $22
  • Meals for Rubraca · 2019-04-04 · $15
  • Meals for Rubraca · 2019-04-04 · $0
Takeda Pharmaceuticals U.S.A.Ninlaro$56
3 payments
  • Meals · 2019-12-03 · $23
  • Meals · 2019-09-11 · $20
  • Meals for Ninlaro · 2019-04-01 · $13
Janssen BiotechImbruvica$44
3 payments
  • Meals for Darzalex · 2019-07-23 · $13
  • Meals for Imbruvica · 2019-06-18 · $19
  • Meals for Imbruvica · 2019-05-10 · $12
Alexion PharmaceuticalsUltomiris$43
2 payments
  • Meals for Ultomiris · 2019-09-05 · $22
  • Meals for Soliris · 2019-05-07 · $21
Novartis PharmaceuticalsKisqali$43
2 payments
  • Meals for Mekinist · 2019-04-18 · $19
  • Meals for Kisqali · 2019-02-19 · $25
Bayer HealthCare PharmaceuticalsVitrakvi$41
2 payments
  • Meals for Stivarga · 2019-10-04 · $16
  • Meals for Vitrakvi · 2019-06-21 · $25
GenzymeElitek$38
2 payments
  • Meals for Elitek · 2019-06-28 · $22
  • Meals for Jevtana · 2019-06-27 · $16
Daiichi SankyoInjectafer$28
1 payment
  • Meals for Injectafer · 2019-06-13 · $28
Lilly USAVerzenio$28
2 payments
  • Meals for Verzenio · 2019-08-27 · $13
  • Meals for Verzenio · 2019-05-07 · $16
ExelixisCabometyx$27
1 payment
  • Meals for Cabometyx · 2019-02-15 · $27
AbbVieVenclexta$25
1 payment
  • Meals for Venclexta · 2019-07-02 · $25
Array BioPharmaBraftovi$24
1 payment
  • Meals for Braftovi · 2019-05-31 · $24
Seattle GeneticsNone$23
1 payment
  • Meals · 2019-09-03 · $23
Lexicon PharmaceuticalsXermelo$22
1 payment
  • Meals for Xermelo · 2019-11-07 · $22
Astellas Pharma USXospata$22
1 payment
  • Meals for Xospata · 2019-12-05 · $22
Agios PharmaceuticalsTibsovo$20
1 payment
  • Meals for Tibsovo · 2019-01-29 · $20
Medtronic USAKyphon Balloon Kyphoplasty$19
1 payment
  • Meals for Kyphon Balloon Kyphoplasty · 2019-09-17 · $19
Gilead SciencesNone$17
1 payment
  • Meals · 2019-09-19 · $17
EisaiLenvima$15
1 payment
  • Meals for Lenvima · 2019-05-14 · $15
Boehringer Ingelheim PharmaceuticalsGilotrif$13
1 payment
  • Meals for Gilotrif · 2019-06-06 · $13

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Genmab U.S., Inc. · Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/Or Metastatic Solid Tumors · 2025Their institution$1,196,131
AstraZeneca AB · A Phase 2b Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi Centre Study To Assess Efficacy and Safety of Multiple Dose Levels of Azd7594 Dpi Given Once Daily for Twelve Weeks, Compared To Placebo, in Asthmatics Symptomatic on Low Dose Ics · 2019Their institution$271,051
Aadi Bioscience, Inc. · Phase 2 Basket Trial of Nab-Sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in Tsc1/ Tsc2 Genes (Precision 1) · 2023Their institution$170,241
AstraZeneca Pharmaceuticals LP · A Phase 2, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan T-Dxd for the Treatment of Unresectable and Or Metastatic Solid Tumors Harboring Her2 Activating Mutations Regardless of Tumor Histology · 2022Their institution$153,727
AstraZeneca Pharmaceuticals LP · A Study of Osimertinib With Or Without Chemotherapy As 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (Flaura2) · 2021Their institution$152,822
Genmab U.S., Inc. · Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/Or Metastatic Solid Tumors · 2024Their institution$148,996
Genmab U.S., Inc. · A Phase 2, Multicenter, Randomized, Open-Label Trial of Gen1046 As Monotherapy and in Combination With Anti-Cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With An Immune Checkpoint Inhibitor · 2023Their institution$131,974
Seagen Inc. · Open-Label Phase 2 Study of Ladiratuzumab Vedotin (Lv) for Unresectable Locally Advanced Or Metastatic Solid Tumors · 2020Their institution$131,369
Merck Sharp & Dohme Corporation · A Phase 3 Study of Pembrolizumab Mk-3475 in Combination With Concurrent Chemoradiation Therapy Followed By Pembrolizumab With Or Without Olaparib Vs Concurrent Chemoradiation Therapy Followed By Durvalumab in Participants With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Nsclc · 2021Their institution$122,199
AstraZeneca Pharmaceuticals LP · A Study of Osimertinib With Or Without Chemotherapy As 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (Flaura2) · 2022Their institution$118,653
Aadi Bioscience, Inc. · A Phase 2 Multi-Center Open-Label Basket Trial of Nab-Sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in Tsc1 Or Tsc2 Genes · 2024Their institution$118,521
Boehringer Ingelheim Pharmaceuticals, Inc. · Brightline-2 Phiia/Iib Brigimadlin Mono in Mdm2 Amp Tumors · 2024Their institution$117,632
AstraZeneca UK Limited · A Phase III,Open Label,Sponsor Blind,Randomized Study of Dato Dxd With Or Without Osimertinib Versus Platinum Based Doublet Chemotherapy for Participants With Egfr Mutated Locally Advanced Or Metastatic Non Small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment Tropion Lung15 · 2025Their institution$112,570
AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (Medi5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed Or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (Evolve-Meso) · 2025Their institution$110,251
Exelixis Inc. · A Randomized Open-Label Phase 3 Study of Xl092 Plus Atezolizumab Vs Regorafenib in Subjects With Metastatic Colorectal Cancer · 2023Their institution$102,579
AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Study of Durvalumab Or Durvalumab and Tremelimumab As Consolidation Treatment for Patients With Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (Adriatic) · 2020Their institution$100,753
AstraZeneca Pharmaceuticals LP · A Phase II, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan T-Dxd, Ds-8201a for the Treatment of Selected Her2-Expressing Tumors Destiny Pantumor02 · 2022Their institution$97,284
AstraZeneca Pharmaceuticals LP · A Phase 2 Study of Tdxd in Patients With Selected Her2 Expressing Tumors · 2021Their institution$93,759
Seagen Inc. · An Open-Label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy With Optional Maintenance Therapy in Subjects With Her2 Expressing Previously Untreated Locally Advanced Or Metastatic Urothelial Cancer · 2023Their institution$93,302
Aadi Bioscience, Inc. · Phase 2 Basket Trial of Nab-Sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in Tsc1tsc2 Genes Precision 1 · 2024Their institution$90,302
Janssen Research & Development, LLC · A Phase 2b, Open-Label, Two-Cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib As First-Line Treatment, Or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy As Second-Line Treatment, for Common Egfr-Mutated Loc · 2025Their institution$86,422
Merck Sharp & Dohme LLC · A Phase 1,2 Dose Escalation,Expansion Study of Ngm707 As Monotherapy and in Combination With Pembrolizumab in Advanced Or Metastatic Solid Tumor Malignancies · 2023Their institution$85,200
Exelixis Inc. · A Randomized Open-Label Phase 3 Study of Xl092 + Atezolizumab Vs Regorafenib in Subjects With Metastatic Colorectal Cancer · 2025Their institution$84,792
AstraZeneca Pharmaceuticals LP · A Phase II Open-Label Multi-Centre Study To Evaluate Safety Tolerability Efficacy Pk and Immunogenicity of Azd0901 As Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 182 · 2024Their institution$78,803
Janssen Research & Development, LLC · A Phase 2b, Open-Label, Two-Cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib As First-Line Treatment, Or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy As Second-Line Treatment, for Common Egfr-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer · 2025Their institution$77,620
Merck Sharp & Dohme LLC · An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of Inbrx 106 and Inbrx-106 in Combination With Pembrolizumab in Subjects With Locally Advanced Or Metastatic Solid Tumors · 2025Their institution$72,520
AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study To Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-Based Chemotherapy in Completely Resected Stage II-III Nsclc Mermaid 1 · 2022Their institution$70,541
Exelixis Inc. · A Randomized Open-Label Phase 3 Study of Xl092 + Atezolizumab Vs Regorafenib in Subjects With Metastatic Colorectal Cancer · 2024Their institution$70,361
Seagen Inc. · A Dose-Escalation and Dose-Expansion Study of Enfortumab Vedotin (Asg-22ce) in Combination With Pembrolizumab and/Or Chemotherapy for Treatment of Patients With Locally Advanced Or Metastatic Urothelial Cancer · 2022Their institution$68,600
AstraZeneca Pharmaceuticals LP · A Phase II Open-Label Multi-Centre Study To Evaluate Safety Tolerability Efficacy Pk and Immunogenicity of Azd0901 As Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 182 · 2025Their institution$65,862
Merck Sharp & Dohme Corporation · An Open-Label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-Line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable Or Metastatic Triple Negative Breast Cancer Tnbc Keylynk 009 · 2020Their institution$63,546
Merck Sharp & Dohme LLC · A Phase III, Randomized, Open-Label Study To Evaluate Pembrolizumab As Neoadjuvant Therapy and in Combination With Standard of Care As Adjuvant Therapy for Stage III-Iva Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma La Hnscc · 2023Their institution$60,246
AstraZeneca UK Limited · Azd9291 Versus Gefitinib Or Erlotinib in Patients With Locally Advanced Or Metastatic Non Small Cell Lung Cancer · 2019Their institution$59,161
EMD Serono, Inc. · A Phase II Single-Arm Trial To Investigate Tepotinib in Advanced (Stage Iiib and IV) Non-Small Cell Lung Cancer With Met Exon 14 (Metex14) Skipping Alterations Or Met Amplification (Vision) · 2020Their institution$58,342
AstraZeneca UK Limited · An Open Label,Single Arm, Phase Two,Multinational,Multicentre Study To Assess the Efficacy and Safety of Five Years of Osimertinib in Participants With Epidermal Growth Factor Receptor Mutation Positive Stage Two 3b Nonsmall Cell Lung Carcinoma, Following Complete Tumour Resection With Or Without Adjuvant Chemotherapy Target · 2024Their institution$57,114
AstraZeneca Pharmaceuticals LP · A Phase III, Randomised, Controlled, Multi-Centre Study of Neoadjuvant Osimertinib As Monotherapy Or in Combination With Chemotherapy Versus Soc Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable, Stages II and Iiia Non-Small Cell Lung Cancer (Neoadaura) · 2022Their institution$56,814
AstraZeneca Pharmaceuticals LP · A Phase II Multicenter Open Label Study To Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan Tdxd for the Treatment of Unresectable and Or Metastatic Solid Tumors Harboring Her2 Activating Mutations Regardless of Tumor Histology · 2021Their institution$56,398
Janssen Research & Development, LLC · A Phase 2b, Open-Label, Two-Cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib As First-Line Treatment, Or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy As Second-Line Treatment, for Common Egfr-Mutated Loc · 2024Their institution$54,690
EMD Serono, Inc. · A Phase II, Open-Label, Single-Arm Study Ofberzosertib (M6620) in Combination Withtopotecan in Participants With Relapsedplatinum-Resistant Small-Cell Lung Cancer · 2021Their institution$51,255
AstraZeneca Pharmaceuticals LP · A Study of Osimertinib With Or Without Chemotherapy As 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (Flaura2) · 2023Their institution$49,774
AstraZeneca Pharmaceuticals LP · A Phase III, Randomised, Controlled, Multi-Centre Study of Neoadjuvant Osimertinib As Monotherapy Or in Combination With Chemotherapy Versus Soc Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable, Stages II and Iiia Non-Small Cell Lung Cancer (Neoadaura) · 2023Their institution$47,595
AstraZeneca Pharmaceuticals LP · Study of Durvalumab Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy · 2021Their institution$47,246
Merck Sharp & Dohme Corporation · A Phase II Trial of Pembrolizumab Mk-3475 in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer Nsclc Keynote-799. · 2020Their institution$45,726
Merck Sharp & Dohme LLC · A Phase III, Randomized, Open-Label Study To Evaluate Pembrolizumab As Neoadjuvant Therapy and in Combination With Standard of Care As Adjuvant Therapy for Stage III-Iva Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma La Hnscc · 2022Their institution$44,700
Seagen Inc. · A Dose-Escalation and Dose-Expansion Study of Enfortumab Vedotin (Asg-22ce) in Combination With Pembrolizumab and/Or Chemotherapy for Treatment of Patients With Locally Advanced Or Metastatic Urothelial Cancer · 2021Their institution$43,853
Seagen Inc. · A Dose-Escalation and Dose-Expansion Study of Enfortumab Vedotin (Asg-22ce) in Combination With Pembrolizumab and/Or Chemotherapy for Treatment of Patients With Locally Advanced Or Metastatic Urothelial Cancer · 2020Their institution$43,715
AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study To Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-Based Chemotherapy in Completely Resected Stage II-III Nsclc Mermaid 1 · 2021Their institution$43,361
Seagen Inc. · Open-Label Phase 2 Study of Ladiratuzumab Vedotin (Lv) for Unresectable Locally Advanced Or Metastatic Solid Tumors · 2021Their institution$42,899
Merck Sharp & Dohme Corporation · A Phase 3 Study of Pembrolizumab Mk-3475 in Combination With Concurrent Chemoradiation Therapy Followed By Pembrolizumab With Or Without Olaparib Vs Concurrent Chemoradiation Therapy Followed By Durvalumab in Participants With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Nsclc · 2020Their institution$42,176
AstraZeneca Pharmaceuticals LP · A Phase II, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan T-Dxd, Ds-8201a for the Treatment of Selected Her2-Expressing Tumors Destiny Pantumor02 · 2023Their institution$42,025
Seagen Inc. · A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With Her2+ Metastatic Colorectal Cancer (Mountaineer) · 2021Their institution$41,819
AstraZeneca Pharmaceuticals LP · This Is A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre, International Study Assessing the Efficacy and Safety of Durvalumab Medi4736 and Domvanalimab Ab154 Compared With Durvalumab Plus Placebo in Adults With Locally Advanced Stage III · 2025Their institution$41,785
AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study To Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-Based Chemotherapy in Completely Resected Stage II-III Nsclc Mermaid 1 · 2023Their institution$41,430
AstraZeneca UK Limited · An Open Label,Single Arm, Phase Two,Multinational,Multicentre Study To Assess the Efficacy and Safety of Five Years of Osimertinib in Participants With Epidermal Growth Factor Receptor Mutation Positive Stage Two 3b Nonsmall Cell Lung Carcinoma, Following Complete Tumour Resection With Or Without Adjuvant Chemotherapy Target · 2025Their institution$40,205
AstraZeneca Pharmaceuticals LP · A Study of Osimertinib With Or Without Chemotherapy As 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (Flaura2) · 2025Their institution$39,966
AstraZeneca UK Limited · An Open Label,Single Arm, Phase Two,Multinational,Multicentre Study To Assess the Efficacy and Safety of Five Years of Osimertinib in Participants With Epidermal Growth Factor Receptor Mutation Positive Stage Two 3b Nonsmall Cell Lung Carcinoma, Following Complete Tumour Resection With Or Without Adjuvant Chemotherapy Target · 2023Their institution$39,755
AstraZeneca Pharmaceuticals LP · A Phase 2, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan T-Dxd for the Treatment of Unresectable and Or Metastatic Solid Tumors Harboring Her2 Activating Mutations Regardless of Tumor Histology · 2023Their institution$39,735
Merck Sharp & Dohme LLC · A Phase 3 Study of Pembrolizumab Mk-3475 in Combination With Concurrent Chemoradiation Therapy Followed By Pembrolizumab With Or Without Olaparib Vs Concurrent Chemoradiation Therapy Followed By Durvalumab in Participants With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Nsclc · 2022Their institution$39,084
Merck Sharp & Dohme Corporation · A Phase III, Randomized, Open-Label Study To Evaluate Pembrolizumab As Neoadjuvant Therapy and in Combination With Standard of Care As Adjuvant Therapy for Stage III-Iva Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma La Hnscc · 2021Their institution$38,619
AstraZeneca Pharmaceuticals LP · This Is A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre, International Study Assessing the Efficacy and Safety of Durvalumab Medi4736 and Domvanalimab Ab154 Compared With Durvalumab Plus Placebo in Adults With Locally Advanced Stage III · 2023Their institution$37,581
Merck Sharp & Dohme Corporation · A Phase III, Randomized, Open-Label Study To Evaluate Pembrolizumab As Neoadjuvant Therapy and in Combination With Standard of Care As Adjuvant Therapy for Stage III-Iva Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma La Hnscc · 2019Their institution$36,999
PFIZER INC. · A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated Locallyadvanced Unresectable Or Metastatic Solid Tumors That Express Her2 · 2024Their institution$34,599
AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study To Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-Based Chemotherapy in Completely Resected Stage II-III Nsclc Mermaid 1 · 2024Their institution$33,417
AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (Medi5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed Or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (Evolve-Meso) · 2024Their institution$32,665
Merck Sharp & Dohme Corporation · A Phase III, Randomized, Open-Label Study To Evaluate Pembrolizumab As Neoadjuvant Therapy and in Combination With Standard of Care As Adjuvant Therapy for Stage III-Iva Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (La Hnscc) · 2019Their institution$32,492
Seagen Inc. · A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated, Locally-Advanced Unresectable Or Metastatic Solid Tumors That Express Her2. · 2023Their institution$31,652
AstraZeneca Pharmaceuticals LP · Phase 2 Multicenter Open-Label Study To Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-Dxd Ds-8201a) for the Treatment of Selected Her2 Expressing Tumours (Destiny-Pantumor02) · 2025Their institution$31,126
AstraZeneca Pharmaceuticals LP · A Study of Osimertinib With Or Without Chemotherapy As 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (Flaura2) · 2020Their institution$30,776
Astellas Pharma Global Development · An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced Or Metastatic Urothelial Carcinoma · 2020Their institution$30,728
AstraZeneca Pharmaceuticals LP · A Phase II, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan T-Dxd, Ds-8201a for the Treatment of Selected Her2-Expressing Tumors Destiny Pantumor02 · 2024Their institution$30,707
AstraZeneca Pharmaceuticals LP · To Assess the Efficacy and Safety of Azd9291 Versus Placebo in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage Ib Iiia Non Small Cell Lung Carcinoma Following Complete Tumour Resection With Or Without Adjuvant Chemotherapy · 2020Their institution$30,622
Seagen Inc. · A Dose-Escalation and Dose-Expansion Study of Enfortumab Vedotin (Asg-22ce) in Combination With Pembrolizumab and/Or Chemotherapy for Treatment of Patients With Locally Advanced Or Metastatic Urothelial Cancer · 2023Their institution$30,220
AstraZeneca Pharmaceuticals LP · A Phase III Randomized Double Blind Multicenter Global Study of Rilvegostomig Or Pembrolizumab in Combination With Platinum Based Chemotherapy for the First Line Treatment of Patients With Metastatic Non Squamous Non Small Cell Lung Cancer Whose Tumors Express Pdl1 Artemide Lung03 · 2025Their institution$28,625
Merck Healthcare KGaA · A Phase II Single-Arm Trial To Investigate Tepotinib in Advanced (Stage Iiib and IV) Non-Small Cell Lung Cancer With Met Exon 14 (Metex14) Skipping Alterations Or Met Amplification (Vision) · 2023Their institution$28,200
AstraZeneca Pharmaceuticals LP · A Phase III, Randomised, Controlled, Multi-Centre Study of Neoadjuvant Osimertinib As Monotherapy Or in Combination With Chemotherapy Versus Soc Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable, Stages II and Iiia Non-Small Cell Lung Cancer (Neoadaura) · 2021Their institution$27,403
PFIZER INC. · A Phase 2b3 Randomized Doubleblind Study To Investigate the Efficacy Safety and Tolerability of Ponsegromab Pf06946860 Compared With Placebo Both With Background Firstline Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma · 2025Their institution$27,388
AstraZeneca Pharmaceuticals LP · An Open-Label, Randomized, Multicenter, Phase 3 Study To Assess the Efficacy and Safety of Trastuzumab Deruxtecan As First-Line Treatment of Unresectable, Locally Advanced Or Metastatic Nsclc Harboring A Her2 Exon 19 Or 20 Mutation (Destiny-Lung04) · 2022Their institution$27,250
Daiichi Sankyo Inc. · Enhertu · 2025Their institution$27,211
AstraZeneca UK Limited · A Global Study To Assess the Effects of Medi4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non Small Cell Lung Cancer · 2020Their institution$27,138
AstraZeneca UK Limited · A Global Study To Assess the Effects of Medi4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non Small Cell Lung Cancer · 2019Their institution$27,032
Merck Sharp & Dohme LLC · A Phase III, Randomized, Open-Label Study To Evaluate Pembrolizumab As Neoadjuvant Therapy and in Combination With Standard of Care As Adjuvant Therapy for Stage III-Iva Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma La Hnscc · 2025Their institution$26,941
Merck Sharp & Dohme Corporation · A Phase III, Randomized, Open-Label Study To Evaluate Pembrolizumab As Neoadjuvant Therapy and in Combination With Standard of Care As Adjuvant Therapy for Stage III-Iva Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma La Hnscc · 2020Their institution$26,220
EMD Serono, Inc. · A Phase II Single-Arm Trial To Investigate Tepotinib in Advanced (Stage Iiib and IV) Non-Small Cell Lung Cancer With Met Exon 14 (Metex14) Skipping Alterations Or Met Amplification (Vision) · 2022Their institution$26,159
AstraZeneca Pharmaceuticals LP · An Open-Label, Randomized, Multicenter, Phase 3 Study To Assess the Efficacy and Safety of Trastuzumab Deruxtecan As First-Line Treatment of Unresectable, Locally Advanced Or Metastatic Nsclc Harboring A Her2 Exon 19 Or 20 Mutation (Destiny-Lung04) · 2023Their institution$26,059
AstraZeneca Pharmaceuticals LP · A Biomarker-Directed Phase 2 Platform Study in Patients With Advanced Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (Orchard) · 2019Their institution$25,815
AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Study of Durvalumab Or Durvalumab and Tremelimumab As Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy Adriatic · 2023Their institution$25,635
Merck Sharp & Dohme LLC · An Open-Label, Randomized Phase 3 Study of Mk-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior Pd-1,L1 and Vegf-Targeted Therapies · 2022Their institution$25,496
BeiGene, Ltd. · A Randomized, Controlled, Open-Label, Global Phase 3 Study Comparing the Efficacy of the Anti-Pd-1 Antibody Tislelizumab (Bgb-A317) Versus Chemotherapy As Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Car · 2023Their institution$25,450
AstraZeneca Pharmaceuticals LP · A Phase Ib Multicenter, Open-Label Dose-Escalation Study To Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-Dxd) and Durvalumab in Combination With Cisplatin, Carboplatin Or Pemetrexed in First-Line Treatment of Patients With Advanced Or Metastatic Non-Squamous Non-Small Cell Lung Cancer (Nsclc) and Human Epidermal Growth Factor Receptor 2 Overexpression (Her2 Positive) (Destiny-Lung03). · 2022Their institution$25,400
Mirati Therapeutics, Inc. · A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With Kras G12c Mutation · 2023Their institution$24,855
Incyte Corporation · A Study of Incmga00012 in Participants With Selected Solid Tumors Pod1um-203 · 2019Their institution$24,769
AstraZeneca Pharmaceuticals LP · A Phase I/Iia Multi-Center, Open-Label Master Protocol To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of Azd8205 in Participants With Advanced Or Metastatic Solid Malignancies · 2025Their institution$24,618
AstraZeneca Pharmaceuticals LP · A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With Egfrm+ and Met+, Locally Advanced Or Metastatic Non-Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib · 2019Their institution$24,065
ABBVIE INC. · A Study To Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Abbv-927 With Abbv-368, Budigalimab (Abbv-181) and Or Chemotherapy in Participants With Locally Advanced Or Metastatic Solid Tumors · 2023Their institution$23,835
Aadi Bioscience, Inc. · A Phase 2 Multi-Center Open-Label Basket Trial of Nab-Sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in Tsc1 Or Tsc2 Genes · 2025Their institution$23,545
Seagen Inc. · An Open-Label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzamab and Mfolfox6 Given With Or Without Either Cetuximab Or Bevacizumab As First-Line Treatment for Subjects With Her2+ Metastatic Colorectal Cancer. · 2022Their institution$22,870
AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study To Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-Based Chemotherapy in Completely Resected Stage II-III Nsclc Mermaid 1 · 2020Their institution$22,399
Mirati Therapeutics, Inc. · A Randomized Phase 3 Study of Mrtx849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With Kras G12c Mutation · 2023Their institution$22,390
Merck Sharp & Dohme LLC · A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and As Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma · 2024Their institution$22,279
AstraZeneca Pharmaceuticals LP · To Assess the Efficacy and Safety of Azd9291 Versus Placebo in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage Ib Iiia Non Small Cell Lung Carcinoma Following Complete Tumour Resection With Or Without Adjuvant Chemotherapy · 2025Their institution$22,108
AstraZeneca Pharmaceuticals LP · A Phase I/Iia Multi-Center, Open-Label Master Protocol To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of Azd8205 in Participants With Advanced Or Metastatic Solid Malignancies · 2023Their institution$21,975
Merck Sharp & Dohme Corporation · A Randomized, Double-Blind, Phase 3 Study of Pemetrexed Platinum Chemotherapy With Or Without Pembrolizumab Mk-3475 in Tki-Resistant Egfr-Mutated Tumors in Metastatic Non-Squamous Non-Small Cell Lung Cancer Nsclc Participants Keynote-789 · 2019Their institution$21,847
Merck Sharp & Dohme Corporation · An Open-Label, Randomized Phase 3 Study of Mk-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior Pd-1,L1 and Vegf-Targeted Therapies · 2021Their institution$21,489
AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Study of Durvalumab Or Durvalumab and Tremelimumab As Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy Adriatic · 2025Their institution$21,478
Merck Healthcare KGaA · A Phase II Single-Arm Trial To Investigate Tepotinib in Advanced (Stage Iiib and IV) Non-Small Cell Lung Cancer With Met Exon 14 (Metex14) Skipping Alterations Or Met Amplification (Vision) · 2024Their institution$20,780
AstraZeneca Pharmaceuticals LP · To Assess the Efficacy and Safety of Azd9291 Versus Placebo in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage Ib Iiia Non Small Cell Lung Carcinoma Following Complete Tumour Resection With Or Without Adjuvant Chemotherapy · 2019Their institution$20,618
Merck Sharp & Dohme Corporation · A Phase II Trial of Pembrolizumab Mk-3475 in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer Nsclc Keynote-799. · 2019Their institution$20,515
Takeda Pharmaceuticals U.S.A., Inc. · A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients - the Insight - Mm Study · 2020Their institution$20,334
AbbVie, Inc. · 2019Their institution$20,191
PFIZER INC. · An Openlabel Randomized Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy With Optional Maintenance Therapy in Subjects With Her2 Expressing Previously Untreated Locally Advanced Or Metastatic Urothelial Cancer · 2024Their institution$20,009
Seattle Genetics, Inc. · Open-Label Phase 2 Study of Ladiratuzumab Vedotin Lv for Unresectable Locally Advanced Or Metastatic Solid Tumors · 2019Their institution$19,468
Takeda Pharmaceuticals U.S.A., Inc. · The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma Insight · 2019Their institution$19,284
Seagen Inc. · An Open-Label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzamab and Mfolfox6 Given With Or Without Either Cetuximab Or Bevacizumab As First-Line Treatment for Subjects With Her2+ Metastatic Colorectal Cancer. · 2023Their institution$19,085
Aadi Bioscience, Inc. · Phase 2 Basket Trial of Nab-Sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in Tsc1/?Tsc2 Genes (Precision 1) · 2025Their institution$19,019
AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Study of Durvalumab Or Durvalumab and Tremelimumab As Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy Adriatic · 2022Their institution$18,906
AstraZeneca UK Limited · A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel As Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (Mcrpc) · 2025Their institution$18,524
Seagen Inc. · Screening Protocol To Detect Her2 Alterations Required for Enrollment on Clinical Research Protocols of Tucatinib · 2021Their institution$18,426
AstraZeneca Pharmaceuticals LP · A Phase III Randomized Multicenter Double-Blind Placebo-Controlled Study of Durvalumab for the Treatment of Stage II-III Nsclc Patients With Minimal Residual Disease Following Surgery and Curative Intent Therapy (Mermaid-2) · 2021Their institution$18,255
EMD Serono, Inc. · A Phase II Single-Arm Trial To Investigate Tepotinib in Advanced (Stage Iiib and IV) Non-Small Cell Lung Cancer With Met Exon 14 (Metex14) Skipping Alterations Or Met Amplification (Vision) · 2021Their institution$18,213
AstraZeneca Pharmaceuticals LP · An Open-Label, Randomized, Multicenter, Phase 3 Study To Assess the Efficacy and Safety of Trastuzumab Deruxtecan As First-Line Treatment of Unresectable, Locally Advanced Or Metastatic Nsclc Harboring A Her2 Exon 19 Or 20 Mutation (Destiny-Lung04) · 2024Their institution$17,517
AstraZeneca Pharmaceuticals LP · A Phase III, Randomised, Controlled, Multi-Centre Study of Neoadjuvant Osimertinib As Monotherapy Or in Combination With Chemotherapy Versus Soc Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable, Stages II and Iiia Non-Small Cell Lung Cancer (Neoadaura) · 2025Their institution$17,066
Seagen Inc. · Open-Label Phase 2 Study of Ladiratuzumab Vedotin (Lv) for Unresectable Locally Advanced Or Metastatic Solid Tumors · 2022Their institution$16,781
AstraZeneca UK Limited · A Global Study To Assess the Effects of Medi4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non Small Cell Lung Cancer · 2022Their institution$15,912
Merck Sharp & Dohme LLC · An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of Inbrx 106 and Inbrx-106 in Combination With Pembrolizumab in Subjects With Locally Advanced Or Metastatic Solid Tumors · 2024Their institution$15,760
Novartis Pharmaceuticals Corporation · Two Arm Randomized Phase 3 Study in High Risk Nsclc Comparing Canakinumab Vs Placebo in Adjuvant Setting · 2021Their institution$15,554
AstraZeneca Pharmaceuticals LP · A Phase III, Randomised, Controlled, Multi-Centre Study of Neoadjuvant Osimertinib As Monotherapy Or in Combination With Chemotherapy Versus Soc Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable, Stages II and Iiia Non-Small Cell Lung Cancer (Neoadaura) · 2024Their institution$15,462
Merck Sharp & Dohme Corporation · An Open-Label, Randomized Phase 3 Study of Mk-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior Pd-1,L1 and Vegf-Targeted Therapies · 2020Their institution$15,453
Seagen Inc. · A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With Her2+ Metastatic Colorectal Cancer (Mountaineer) · 2020Their institution$15,394
Genmab U.S., Inc. · A Phase 2, Multicenter, Randomized, Open-Label Trial of Gen1046 As Monotherapy and in Combination With Anti-Cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With An Immune Checkpoint Inhibitor · 2024Their institution$15,267
AstraZeneca Pharmaceuticals LP · A Phase Ib Multicenter, Open-Label Dose-Escalation Study To Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-Dxd) and Durvalumab in Combination With Cisplatin, Carboplatin Or Pemetrexed in First-Line Treatment of Patients With Advanced Or Metastatic Non-Squamous Non-Small Cell Lung Cancer (Nsclc) and Human Epidermal Growth Factor Receptor 2 Overexpression (Her2 Positive) (Destiny-Lung03). · 2023Their institution$15,106
AbbVie Inc. · Venclexta · 2020Their institution$15,100
AstraZeneca UK Limited · Azd9291 Versus Gefitinib Or Erlotinib in Patients With Locally Advanced Or Metastatic Non Small Cell Lung Cancer · 2020Their institution$14,659
Merck Sharp & Dohme LLC · A Phase III, Randomized, Open-Label Study To Evaluate Pembrolizumab As Neoadjuvant Therapy and in Combination With Standard of Care As Adjuvant Therapy for Stage III-Iva Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma La Hnscc · 2024Their institution$14,507
ABBVIE INC. · A Phase 1, Multicenter, Open-Label Study To Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of Abbv-927 With Abbv-368, Budigalimab (Abbv-181) and/Or Chemotherapy in Subjects With Locally Advanced Or Metastatic Solid Tumors · 2021Their institution$14,500
Merck Sharp & Dohme Corporation · A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiationand As Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advancedhead and Neck Squamous Cell Carcinoma · 2019Their institution$14,421
Boehringer Ingelheim Pharmaceuticals, Inc. · Brightline-2: A Phase Iia/Iib, Open-Label, Single-Arm, Multi-Centre Trial of Bi 907828 (Brigimadlin) for Treatment of Patients With Locally Advanced / Metastatic, Mdm2 Amplified, Tp53 Wild-Type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Or Other Selected Solid Tumours · 2025Their institution$14,371
Merck Sharp & Dohme LLC · A Phase 1,2 Dose Escalation,Expansion Study of Ngm707 As Monotherapy and in Combination With Pembrolizumab in Advanced Or Metastatic Solid Tumor Malignancies · 2024Their institution$14,200
AstraZeneca Pharmaceuticals LP · A Global Study To Assess the Effects of Medi4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non Small Cell Lung Cancer · 2019Their institution$13,892
AstraZeneca Pharmaceuticals LP · A Phase Two Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With Egfrmpplus and Metplus,Locally Advanced Or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib · 2022Their institution$13,879
AstraZeneca Pharmaceuticals LP · To Assess the Efficacy and Safety of Azd9291 Versus Placebo in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage Ib Iiia Non Small Cell Lung Carcinoma Following Complete Tumour Resection With Or Without Adjuvant Chemotherapy · 2023Their institution$13,763
AstraZeneca Pharmaceuticals LP · This Is A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre, International Study Assessing the Efficacy and Safety of Durvalumab Medi4736 and Domvanalimab Ab154 Compared With Durvalumab Plus Placebo in Adults With Locally Advanced Stage III · 2024Their institution$13,343
Merck Sharp & Dohme Corporation · A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab Mk-3475 As Neoadjuvant,Adjuvant Therapy for Participants With Resectable Stage Iib Or Iiia Non-Small Cell Lung Cancer Nsclc Keynote-671 · 2019Their institution$13,273
AstraZeneca Pharmaceuticals LP · To Assess the Efficacy and Safety of Azd9291 Versus Placebo in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage Ib Iiia Non Small Cell Lung Carcinoma Following Complete Tumour Resection With Or Without Adjuvant Chemotherapy · 2021Their institution$12,428
AstraZeneca Pharmaceuticals LP · A Phase I/Iia Multi-Center, Open-Label Master Protocol To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of Azd8205 in Participants With Advanced Or Metastatic Solid Malignancies · 2024Their institution$11,760
Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advancedmetastatic Or Surgically Unresectable Solid Tumor Malignancies Harboring Activating Fgfr Mutations Or Translocations Fight-207 · 2019Their institution$11,536
Boehringer Ingelheim International GmbH · Ph1 Mono/Combi+Pd1 in Advanced Tumours · 2020Their institution$11,025
Takeda Pharmaceuticals U.S.A., Inc. · A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients - the Insight - Mm Study · 2021Their institution$10,806
Incyte Corporation · A Phase 1, Open-Label Study To Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment · 2020Their institution$10,795
AstraZeneca UK Limited · A Global Study To Assess the Effects of Medi4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non Small Cell Lung Cancer · 2021Their institution$10,439
AstraZeneca Pharmaceuticals LP · A Phase III Randomized Multicenter Double-Blind Placebo-Controlled Study of Durvalumab for the Treatment of Stage II-III Nsclc Patients With Minimal Residual Disease Following Surgery and Curative Intent Therapy (Mermaid-2) · 2022Their institution$10,300
Genmab U.S., Inc. · A Phase 2, Multicenter, Randomized, Open-Label Trial of Gen1046 As Monotherapy and in Combination With Anti-Cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With An Immune Checkpoint Inhibitor · 2025Their institution$9,852
AstraZeneca UK Limited · An Open Label Multi Centre Safety Study of Fixed Dose Durvalumab Plus Tremelimumab Combination Therapy Or Durvalumab Monotherapy in Advanced Solid Malignancies Strong · 2020Their institution$9,612
Merck Sharp & Dohme Corporation · An Open-Label, Randomized Phase 3 Study of Mk-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior Pd-1,L1 and Vegf-Targeted Therapies · 2019Their institution$9,480
Merck Sharp & Dohme LLC · A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and As Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma · 2022Their institution$9,096
Halozyme Inc · A Phase 1b Open-Label Study of Pegylated Recombinant Human Hyaluronidase (Pegph20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan-High Solid Tumors · 2019Their institution$8,747
Astellas Pharma Global Development · A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (Adt) Versus Placebo Plus Adt in Patients With Metastatic Hormone Sensitive Prostate Cancer (Mhspc) · 2022Their institution$8,654
AstraZeneca UK Limited · An Open Label Multi Centre Safety Study of Fixed Dose Durvalumab Plus Tremelimumab Combination Therapy Or Durvalumab Monotherapy in Advanced Solid Malignancies Strong · 2021Their institution$8,445
Merck Sharp & Dohme LLC · A Phase II Trial of Pembrolizumab Mk-3475 in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer Nsclc Keynote-799. · 2022Their institution$8,250
Merck Sharp & Dohme Corporation · A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab Mk-3475 As Neoadjuvant,Adjuvant Therapy for Participants With Resectable Stage II, Iiia, and Resectable Iiib T3-4n2 Non-Small Cell Lung Cancer Nsclc Keynote-671 · 2020Their institution$7,813
AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Study of Durvalumab Or Durvalumab and Tremelimumab As Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy Adriatic · 2024Their institution$7,790
Seagen Inc. · A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With Her2+ Metastatic Colorectal Cancer (Mountaineer) · 2022Their institution$7,762
AstraZeneca Pharmaceuticals LP · A Biomarker-Directed Phase 2 Platform Study in Patients With Advanced Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (Orchard) · 2020Their institution$7,594
Merck Sharp & Dohme LLC · A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and As Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma · 2025Their institution$7,353
AstraZeneca Pharmaceuticals LP · To Assess the Efficacy and Safety of Azd9291 Versus Placebo in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage Ib Iiia Non Small Cell Lung Carcinoma Following Complete Tumour Resection With Or Without Adjuvant Chemotherapy · 2022Their institution$7,255
Eli Lilly and Company · A Randomized Phase 2 Trial of Am0010 in Combination With Pembrolizumab Vs. Pembrolizumab Alone As First-Line Therapy in Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Have High Pd-L1 Expression · 2020Their institution$7,206
AbbVie Inc. · 2020Their institution$7,069
Eli Lilly and Company · A Randomized Phase 2 Trial of Am0010 in Combination With Nivolumab Vs. Nivolumab Alone As Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of Pd-L1 · 2020Their institution$6,420
Merck Healthcare KGaA · A Phase II Single-Arm Trial To Investigate Tepotinib in Advanced (Stage Iiib and IV) Non-Small Cell Lung Cancer With Met Exon 14 (Metex14) Skipping Alterations Or Met Amplification (Vision) · 2025Their institution$6,347
AstraZeneca UK Limited · An Open Label Multi Centre Safety Study of Fixed Dose Durvalumab Plus Tremelimumab Combination Therapy Or Durvalumab Monotherapy in Advanced Solid Malignancies Strong · 2019Their institution$5,422
AstraZeneca Pharmaceuticals LP · A Biomarker-Directed Phase 2 Platform Study in Patients With Advanced Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (Orchard) · 2021Their institution$5,419
Merck Sharp & Dohme LLC · A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and As Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma · 2023Their institution$5,392
AstraZeneca Pharmaceuticals LP · An Open-Label, Randomized, Multicenter, Phase 3 Study To Assess the Efficacy and Safety of Trastuzumab Deruxtecan As First-Line Treatment of Unresectable, Locally Advanced Or Metastatic Nsclc Harboring A Her2 Exon 19 Or 20 Mutation (Destiny-Lung04) · 2025Their institution$5,340
PFIZER INC. · A Phase 3 Randomized Openlabel Multicenter Trial of Arv471 Pf07850327 Vs Fulvestrant in Participants With Estrogen Receptorpositive Her2negative Advanced Breast Cancer Whose Disease Progressed After Prior Endocrine Based Treatment for Advanced Disease Veritac2 · 2023Their institution$5,300
ABBVIE INC. · A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (Nsclc) With High Programmed Cell Death Ligand-1 (Pd-L1) Expression · 2022Their institution$5,000
PFIZER INC. · A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated Locallyadvanced Unresectable Or Metastatic Solid Tumors That Express Her2 · 2025Their institution$4,860
AstraZeneca Pharmaceuticals LP · A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With Egfrm+ and Met+, Locally Advanced Or Metastatic Non-Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib · 2020Their institution$4,708
Seagen Inc. · Screening Protocol To Detect Her2 Alterations Required for Enrollment on Clinical Research Protocols of Tucatinib · 2022Their institution$4,300
Merck Sharp & Dohme Corporation · A Phase II Trial of Pembrolizumab Mk-3475 in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer Nsclc Keynote-799. · 2021Their institution$4,232
Takeda Pharmaceuticals U.S.A., Inc. · A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients - the Insight - Mm Study · 2022Their institution$4,170
Merck Sharp & Dohme Corporation · A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and As Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma · 2020Their institution$4,161
Halozyme Inc · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Pegylated Recombinant Human Hyaluronidase (Pegph20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects Wit · 2019Their institution$4,124
Merck Sharp & Dohme Corporation · A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and As Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma · 2021Their institution$3,982
Merck Sharp & Dohme Corporation · A Multicenter, Open-Label, Phase 2 Basket Study To Evaluate the Safety and Efficacy of Mk-2140 As A Monotherapy and in Combination in Participants With Aggressive and Indolent B-Cell Malignancies. · 2021Their institution$3,869
PFIZER INC. · A Phase 3 Randomized Openlabel Multicenter Trial of Arv471 Pf07850327 Vs Fulvestrant in Participants With Estrogen Receptorpositive Her2negative Advanced Breast Cancer Whose Disease Progressed After Prior Endocrine Based Treatment for Advanced Disease Veritac2 · 2025Their institution$3,800
Takeda Pharmaceuticals U.S.A., Inc. · The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma Insight · 2019This clinician$3,705
Eli Lilly and Company · A Randomized Phase 2 Trial of Am0010 in Combination With Pembrolizumab Vs. Pembrolizumab Alone As First-Line Therapy in Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Have High Pd-L1 Expression · 2019Their institution$3,693
Astellas Pharma Global Development · A Multinational Phase 3 Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (Adt) Versus Placebo Plus Adt in Patients With Metastatic Hormone Sensitive Prostate Cancer (Mhspc) · 2021Their institution$3,366
GlaxoSmithKline, LLC. · A Randomized, Double-Blind, Adaptive, Phase II/III Study of Gsk3359609 · 2020Their institution$3,100
Merck Sharp & Dohme Corporation · A Phase II Clinical Trial of Single Agent Pembrolizumab Mk-3475 in Subjects With Recurrent Or Metastatic Head and Neck Squamous Cell Carcinoma Hnscc Who Have Failed Platinum and Cetuximab · 2019Their institution$3,050
Merck Sharp & Dohme Corporation · An Open-Label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-Line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable Or Metastatic Triple Negative Breast Cancer Tnbc Keylynk 009 · 2021Their institution$3,025
AstraZeneca Pharmaceuticals LP · A Study of Osimertinib With Or Without Chemotherapy As 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (Flaura2) · 2024Their institution$2,937
Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic Or Surgically Unresectable Solid Tumor Malignancies Harboring Activating Fgfr Mutations Or Translocations (Fight-207) · 2021Their institution$2,653
Merck Sharp & Dohme Corporation · Phase 2, Open-Label, Single Arm Study To Evaluate the Safety Andefficacy of Pembrolizumab in Participants With Recurrent Or Metastatic Cutaneous Squamous Cell Carcinoma R,M Cscc · 2019Their institution$2,600
AstraZeneca Pharmaceuticals LP · A Biomarker-Directed Phase 2 Platform Study in Patients With Advanced Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (Orchard) · 2022Their institution$2,580
Merck Sharp & Dohme LLC · A Phase II Trial of Pembrolizumab Mk-3475 in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer Nsclc Keynote-799. · 2024Their institution$2,500
AstraZeneca Pharmaceuticals LP · A Phase III Randomized Multicenter Double-Blind Placebo-Controlled Study of Durvalumab for the Treatment of Stage II-III Nsclc Patients With Minimal Residual Disease Following Surgery and Curative Intent Therapy (Mermaid-2) · 2023Their institution$2,500
Astellas Pharma Global Development · A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy Adt Versus Placebo Plus Adt in Patients With Metastatic Hormone Sensitive Prostate Cancer Mhspc · 2019Their institution$2,369
ABBVIE INC. · A Study To Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Abbv-927 With Abbv-368, Budigalimab (Abbv-181) and Or Chemotherapy in Participants With Locally Advanced Or Metastatic Solid Tumors · 2024Their institution$2,340
ABBVIE INC. · A Study To Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Abbv-927 With Abbv-368, Budigalimab (Abbv-181) Andx2for Chemotherapy in Participants With Locally Advanced Or Metastatic Solid Tumors · 2022Their institution$2,320
ABBVIE INC. · A Phase 1b Study of Venetoclax in Combination With Pembrolizumab in Subjects With Previously Untreated Nsclc Whose Tumors Have High Pd-L1 Expression · 2021Their institution$2,275
GlaxoSmithKline, LLC. · A Randomized, Double-Blind, Adaptive, Phase II/III Study of Gsk3359609 · 2022Their institution$2,200
Boehringer Ingelheim Pharma GmbH & Co.KG · Ph1 Mono/Combi+Pd1 in Advanced Tumours · 2020Their institution$2,174
Boehringer Ingelheim Pharma GmbH & Co.KG · Brightline-2 Phiia/Iib Brigimadlin Mono in Mdm2 Amp Tumors · 2024Their institution$2,052
PFIZER INC. · An Openlabel Randomized Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced Or Metastatic Urothelial Carcinoma That Expresses Her2 Ihc 1 and Greater · 2024Their institution$2,040
Mirati Therapeutics, Inc. · A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With Kras G12c Mutation · 2024Their institution$2,030
PFIZER INC. · A Phase II Open Label Study of Tucatinib Combined With Trastuzumab in Patients With Her2 Metastatic Colorectal Cancer Mountaineer · 2024Their institution$2,000
Novartis Pharmaceuticals Corporation · Two Arm Randomized Phase 3 Study in High Risk Nsclc Comparing Canakinumab Vs Placebo in Adjuvant Setting · 2022Their institution$1,924
AstraZeneca Pharmaceuticals LP · A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With Egfrm+ and Met+, Locally Advanced Or Metastatic Non-Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib · 2021Their institution$1,611
AstraZeneca Pharmaceuticals LP · Study of 1st Line Therapy Study of Medi4736 With Tremelimumab Versus Soc in Non Small Cell Lung Cancer Nsclc Neptune · 2019Their institution$1,528
AstraZeneca UK Limited · A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel As Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (Mcrpc) · 2023Their institution$1,486
AstraZeneca Pharmaceuticals LP · To Assess the Efficacy and Safety of Azd9291 Versus Placebo in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage Ib Iiia Non Small Cell Lung Carcinoma Following Complete Tumour Resection With Or Without Adjuvant Chemotherapy · 2024Their institution$1,411
PFIZER INC. · A Phase 3 Randomized Openlabel Multicenter Trial of Arv471 Pf07850327 Vs Fulvestrant in Participants With Estrogen Receptorpositive Her2negative Advanced Breast Cancer Whose Disease Progressed After Prior Endocrine Based Treatment for Advanced Disease Veritac2 · 2024Their institution$1,350
Incyte Corporation · A Study of Incmga00012 in Participants With Selected Solid Tumors (Pod1um-203) · 2020Their institution$1,306
Astellas Pharma Global Development · A Study of Enzalutamide Plus Androgen Deprivation Therapy (Adt) Versus Placebo Plus Adt in Patients With Metastatic Hormone Sensitive Prostate Cancer (Mhspc) · 2020Their institution$1,282
Eli Lilly and Company · A Randomized Phase 2 Trial of Am0010 in Combination With Nivolumab Vs. Nivolumab Alone As Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of Pd-L1 · 2019Their institution$1,251
Seagen Inc. · A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With Her2+ Metastatic Colorectal Cancer (Mountaineer) · 2023Their institution$1,225
Merck Sharp & Dohme Corporation · A Phase III Study of Pembrolizumab Vs Chemotherapy in Microsatellite Instability- High Or Mismatched Repair Deficient Colorectal Carcinoma · 2019Their institution$1,100
Puma Biotechnology, Inc. · A Randomized, Double-Blind, Placebo-Controlled Trial of Neratinib · 2019Their institution$720
Boehringer Ingelheim International GmbH · Ph1 Mono/Combi+Pd1 in Advanced Tumours · 2021Their institution$675
Merck Sharp & Dohme LLC · A Phase II Trial of Pembrolizumab Mk-3475 in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer Nsclc Keynote-799. · 2025Their institution$670
PUMA BIOTECHNOLOGY, INC. · A Randomized, Double-Blind, Placebo-Controlled Trial of Neratinib (Hki-272) After Trastuzumab in Women With Early-Stage Her-2/Neu Overexpressed/Amplified Breast Cancer · 2020Their institution$600
Boehringer Ingelheim International GmbH · Brightline-2 Phiia/Iib Brigimadlin Mono in Mdm2 Amp Tumors · 2024Their institution$576
AstraZeneca Pharmaceuticals LP · Study of 1st Line Therapy Study of Medi4736 With Tremelimumab Versus Soc in Non Small Cell Lung Cancer Nsclc Neptune · 2020Their institution$538
Merck Sharp & Dohme Corporation · A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab Vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-Small Cell Lung Cancer Subjects Whose Tumors Are Pd-L1 Positive Tps 50 · 2019Their institution$500
AstraZeneca UK Limited · Azd9291 Versus Gefitinib Or Erlotinib in Patients With Locally Advanced Or Metastatic Non Small Cell Lung Cancer · 2022Their institution$457
Merck Sharp & Dohme Corporation · A Phase III, Multicenter, Randomized Study To Evaluate Mk 1308a Co-Formulated Mk 1308,Mk 3475 Versus Chemotherapy As Adjuvant Therapy Following Surgery in Participants With Microsatellite Instability-High Msi-H Or Mismatch Repair Deficient Dmmr High Risk Stage III Colorectal Cancer Mk 1308a-007 Aim-High · 2021Their institution$344
PFIZER INC. · A Doseescalation and Doseexpansion Study of Enfortumab Vedotin Asg22ce in Combination With Pembrolizumab Andor Chemotherapy for Treatment of Patients With Locally Advanced Or Metastatic Urothelial Cancer · 2024Their institution$300
E.R. Squibb & Sons, L.L.C. · Trident-1 - Ros1+ Nsclc - Primary Study - A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Tpx-0005 in Patients With Advanced Solid Tumors Harboring Alk, Ros1, Or Ntrk1-3 · 2023Their institution$290
Seagen Inc. · Open-Label Phase 2 Study of Ladiratuzumab Vedotin (Lv) for Unresectable Locally Advanced Or Metastatic Solid Tumors · 2023Their institution$245
Seagen Inc. · Screening Protocol To Detect Her2 Alterations Required for Enrollment on Clinical Research Protocols of Tucatinib · 2023Their institution$100
AstraZeneca UK Limited · Azd9291 Versus Gefitinib Or Erlotinib in Patients With Locally Advanced Or Metastatic Non Small Cell Lung Cancer · 2021Their institution$57
Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic Or Surgically Unresectable Solid Tumor Malignancies Harboring Activating Fgfr Mutations Or Translocations (Fight-207) · 2022Their institution$18

Professional record

NPI
1518055573
Licence
CA A49481California A49481: Current · expires 2027-11-30
Trained
Duke University School of Medicine, 1988 · 38 years ago
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Medicaid ID
CA 00A494810
Taxonomy
Federal specialty code 207RH0003X (207RH0003X); Federal specialty code 207RH0000X (207RH0000X); Medical oncology (207RX0202X)
Mailing address
3555 Round Barn Cir, Santa Rosa, CA, 95403
NPI first listed
2006-10-11
NPI last updated
2021-10-14
NPI record certified
2021-10-14

This is when the NPI record was last certified, not a medical board exam.

This office lists an electronic records connection.